1
|
Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart JE, Hoogenboom JD, Urbano-Ispizua A, Peters S, Kuball J, Kröger N, Sureda A, Chabannon C, Haanen J, Pedrazzoli P. Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey. Ann Oncol 2024; 35:404-406. [PMID: 38145867 DOI: 10.1016/j.annonc.2023.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 12/09/2023] [Accepted: 12/17/2023] [Indexed: 12/27/2023] Open
Affiliation(s)
- P Comoli
- Cell Factory and Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | | | - A Ruggeri
- Pediatric Hematology and BMT Unit, San Raffaele Scientific Institute, Milan, Italy
| | - U Koehl
- Institute of Clinical Immunology and Fraunhofer Institute for Cell Therapy and Immunology, Leipzig
| | - F Lordick
- Medical Oncology, Universitätsklinikum Leipzig, Leipzig, Germany
| | | | | | - A Urbano-Ispizua
- Hematology Department, Clinic University Hospital, Barcellona, Spain
| | - S Peters
- Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - J Kuball
- Department of Hematology and Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands
| | - N Kröger
- University Medical Center Hamburg, Hamburg, Germany
| | - A Sureda
- Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain
| | - C Chabannon
- Centre de Thérapie Cellulaire & Centre d'Investigations Cliniques en Biothérapies Inserm CBT-1409, Institut Paoli-Calmettes, Marseille, Cedex, France
| | - J Haanen
- Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - P Pedrazzoli
- Oncology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Dept of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
| |
Collapse
|
2
|
Montserrat-Mesquida M, Ferrer MD, Pons A, Sureda A, Capó X. Effects of chronic hydrogen peroxide exposure on mitochondrial oxidative stress genes, ROS production and lipid peroxidation in HL60 cells. Mitochondrion 2024; 76:101869. [PMID: 38467292 DOI: 10.1016/j.mito.2024.101869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 02/25/2024] [Accepted: 03/07/2024] [Indexed: 03/13/2024]
Abstract
Hydrogen peroxide (H2O2) is a reactive species that is also involved in the redox regulation of cells because of it is relative stability. In numerous pathological situations, a chronic increase in the production of reactive species is observed, which is related to oxidative stress and cellular damage. This study aimed to evaluate the effects of long-term exposure to different H2O2 concentrations on oxidative stress biomarkers and mitochondrial dynamics in HL60 cells. HL60 cells were treated with a sustained production (0.1, 1.0 and 10.0 nM/s) of H2O2 for one hour. H2O2 production and malondialdehyde (MDA) levels, as a lipid peroxidation marker, increased progressively in HL60 cells in accordance with higher H2O2 exposure, with significant differences between the 10 nM/s H2O2 group and the control and 0.1 nM/s groups. Similarly, progressive increased expression in genes related to the mitochondrial antioxidant defences and mitochondrial dynamics were also observed. Significantly increased gene expression in the 10 nM/s H2O2 with respect to the control group was observed for manganese superoxide dismutase (MnSOD), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PCG1α), nuclear respiratory factor 2 (Nrf2), mitochondrial transcription factor A (Tfam), mitofusins 1 and 2 (Mfn1 and Mfn2) and uncoupling protein 3 (UCP3), whereas no significant changes were observed in the cytochrome c oxidase subunit IV (COXIV) gene expression. In conclusion, exposure to different sustained production of H2O2 is related to a progressive increase in the gene expression of mitochondrial dynamics and redox processes in HL60 cells, but also to oxidative damage at higher H2O2 production levels.
Collapse
Affiliation(s)
- M Montserrat-Mesquida
- Research Group in Community Nutrition and Oxidative Stress, University of the Balearic Islands-IUNICS, 07122 Palma, Spain; Health Research Institute of Balearic Islands (IdISBa), 07120 Palma, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
| | - M D Ferrer
- Research Group in Community Nutrition and Oxidative Stress, University of the Balearic Islands-IUNICS, 07122 Palma, Spain
| | - A Pons
- Research Group in Community Nutrition and Oxidative Stress, University of the Balearic Islands-IUNICS, 07122 Palma, Spain; Health Research Institute of Balearic Islands (IdISBa), 07120 Palma, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
| | - A Sureda
- Research Group in Community Nutrition and Oxidative Stress, University of the Balearic Islands-IUNICS, 07122 Palma, Spain; Health Research Institute of Balearic Islands (IdISBa), 07120 Palma, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
| | - X Capó
- Research Group in Community Nutrition and Oxidative Stress, University of the Balearic Islands-IUNICS, 07122 Palma, Spain; Translational Research in Aging and Longevity (TRIAL) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain
| |
Collapse
|
3
|
Mussetti A, Rius-Sansalvador B, Moreno V, Peczynski C, Polge E, Galimard JE, Kröger N, Blaise D, Peffault de Latour R, Kulagin A, Mousavi A, Stelljes M, Hamladji RM, Middeke JM, Salmenniemi U, Sengeloev H, Forcade E, Platzbecker U, Reményi P, Angelucci E, Chevallier P, Yakoub-Agha I, Craddock C, Ciceri F, Schroeder T, Aljurf M, Ch K, Moiseev I, Penack O, Schoemans H, Mohty M, Glass B, Sureda A, Basak G, Peric Z. Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study. Bone Marrow Transplant 2024; 59:232-238. [PMID: 38007531 DOI: 10.1038/s41409-023-02147-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 10/04/2023] [Accepted: 11/03/2023] [Indexed: 11/27/2023]
Abstract
Allogeneic haematopoietic cell transplantation (alloHCT) has curative potential counterbalanced by its toxicity. Prognostic scores fail to include current era patients and alternative donors. We examined adult patients from the EBMT registry who underwent alloHCT between 2010 and 2019 for oncohaematological disease. Our primary objective was to develop a new prognostic score for overall mortality (OM), with a secondary objective of predicting non-relapse mortality (NRM) using the OM score. AI techniques were employed. The model for OM was trained, optimized, and validated using 70%, 15%, and 15% of the data set, respectively. The top models, "gradient boosting" for OM (AUC = 0.64) and "elasticnet" for NRM (AUC = 0.62), were selected. The analysis included 33,927 patients. In the final prognostic model, patients with the lowest score had a 2-year OM and NRM of 18 and 13%, respectively, while those with the highest score had a 2-year OM and NRM of 82 and 93%, respectively. The results were consistent in the subset of the haploidentical cohort (n = 4386). Our score effectively stratifies the risk of OM and NRM in the current era but do not significantly improve mortality prediction. Future prognostic scores can benefit from identifying biological or dynamic markers post alloHCT.
Collapse
Affiliation(s)
- A Mussetti
- Department of Haematology, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - B Rius-Sansalvador
- Biomarkers and Susceptibility Unit (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - V Moreno
- Biomarkers and Susceptibility Unit (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Peczynski
- EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM Unité Mixte de Recherche (UMR)-S 938, Sorbonne University, Paris, France
| | - E Polge
- EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukaemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France
| | | | - N Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Blaise
- Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
| | - R Peffault de Latour
- Service d'Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
- Université Paris Diderot, Institut Universitaire d'Hématologie, Sorbonne Paris Cité, Paris, France
| | - A Kulagin
- Raisa Memorial (RM) Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia
| | - A Mousavi
- Shariati Hospital, Haematology-Oncology and BMT Research, Tehran, Islamic Republic of Iran
| | - M Stelljes
- Department of Medicine A, University Hospital Münster, Münster, Germany
| | - R M Hamladji
- Centre Pierre et Marie Curie, Service Hématologie Greffe de Moëlle, Alger, Algeria
| | - J M Middeke
- Med. Klinik I, University Hospital, TU Dresden, Germany
| | - U Salmenniemi
- HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland
| | - H Sengeloev
- Bone Marrow Transplant Unit Copenhagen, Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - E Forcade
- CHU Bordeaux, Service d'hématologie Clinique et Thérapie Cellulaire, 33000, Pessac, France
| | | | - P Reményi
- Department of Haematology and Stem Cell Transplant, Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary
| | - E Angelucci
- Haematology and Cellular Therapy Unit. IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | | | - I Yakoub-Agha
- CHU de Lille LIRIC, INSERM U995, Université de Lille, Lille, France
| | - C Craddock
- Department of Haematology, University Hospital Birmingham NHS Trust, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK
| | - F Ciceri
- Haematology & Bone Marrow Transplant, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - T Schroeder
- Department of Bone Marrow Transplantation, University Hospital, Essen, Germany
| | - M Aljurf
- Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | | | - I Moiseev
- R.M.Gorbacheva Memorial Institute of Oncology, Haematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation
| | - O Penack
- Department of Haematology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - H Schoemans
- Department of Haematology, University Hospitals Leuven, Leuven, Belgium
- Department of Public Health and Primary Care, ACCENT VV, KU Leuven - University of Leuven, Leuven, Belgium
| | - M Mohty
- Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France
| | - B Glass
- Klinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | - A Sureda
- Department of Haematology, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
| | - G Basak
- Department of Haematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
| | - Z Peric
- School of medicine, University of Zagreb and University Hospital Centre Zagreb, Zagreb, Croatia
| |
Collapse
|
4
|
Peña M, Montané C, Paviglianiti A, Hurtado L, González S, Carro I, Maluquer C, Domingo-Domenech E, Gonzalez-Barca E, Sureda A, Mussetti A. Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas. Bone Marrow Transplant 2023; 58:1282-1285. [PMID: 37626265 DOI: 10.1038/s41409-023-02069-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 07/05/2023] [Accepted: 07/21/2023] [Indexed: 08/27/2023]
Affiliation(s)
- M Peña
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
| | - C Montané
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
| | - A Paviglianiti
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
| | - L Hurtado
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - S González
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - I Carro
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
| | - C Maluquer
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
| | - E Domingo-Domenech
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
| | - E Gonzalez-Barca
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
- Bellvitge Health Sciences Campus, University of Barcelona, Barcelona, Spain
| | - A Sureda
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
- Bellvitge Health Sciences Campus, University of Barcelona, Barcelona, Spain
| | - A Mussetti
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
| |
Collapse
|
5
|
Fabbri N, Mussetti A, Sureda A. Second-line treatment of diffuse large B-cell lymphoma: Evolution of options. Semin Hematol 2023; 60:305-312. [PMID: 38342663 DOI: 10.1053/j.seminhematol.2023.12.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 11/24/2023] [Accepted: 12/04/2023] [Indexed: 02/13/2024]
Abstract
In the era of immunochemotherapy, approximately 60%-70% of diffuse large B-cell lymphoma (DLBCL) patients achieve remission with first-line rituximab-based chemoimmunotherapy. However, 30%-40% relapse after initial response to first-line therapy and, out of them, 20%-50% are refractory or experience early relapse. The second-line therapy algorithm for DLBCL has recently evolved, thanks to the recent approval of new therapeutic agents or their combinations. The new guidelines suggest a stratification of relapsed/refractory (R/R) DLBCL based on the time to relapse. For transplant-eligible patients, autologous stem cell transplant remains the preferred option when the patient relapses after 12 months from diagnosis, while anti-CD19 CART-cell therapy is the current preferred choice for high-risk DLBCL, defined as primary refractory or relapse ≤12 months. For transplant-ineligible or CAR T-cell therapy-ineligible patients, the therapeutic arsenal historically lacked effective options. However, new therapeutic options, including polatuzumab vedotin combined with bendamustine-rituximab and tafasitamab with lenalidomide, have been recently approved, and novel agents such as loncastuximab tesirine, selinexor, anti-CD19 CAR T-cell therapy, and bispecific antibodies have shown promising efficacy and manageable safety in this setting offering new hope to patients in this challenging scenario.
Collapse
Affiliation(s)
- N Fabbri
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - A Mussetti
- Clinical Hematology Department, Institut Català d'Oncologia - L'Hospitalet de Llobregat, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
| | - A Sureda
- Clinical Hematology Department, Institut Català d'Oncologia - L'Hospitalet de Llobregat, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
| |
Collapse
|
6
|
Arribas I, Maluquer C, Pomares H, Carro I, Baca C, Bosch A, Arévalo CE, Montané C, Ribes-Amorós J, Zamora L, Granada I, Gamundi E, Arnan M, Sureda A. B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature. Leuk Lymphoma 2023; 64:1701-1705. [PMID: 37455651 DOI: 10.1080/10428194.2023.2234527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Accepted: 06/30/2023] [Indexed: 07/18/2023]
Affiliation(s)
- I Arribas
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - C Maluquer
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - H Pomares
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - I Carro
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - C Baca
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - A Bosch
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - C E Arévalo
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - C Montané
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - J Ribes-Amorós
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - L Zamora
- Hematology Department, ICO-Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain
| | - I Granada
- Hematology Department, ICO-Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain
| | - E Gamundi
- Pathology Department, Bellvitge University Hospital, Barcelona, Spain
| | - M Arnan
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - A Sureda
- Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
7
|
Olivares J, Masmiquel L, Del Campo R, Costa A, Cladera A, Amer N, Sureda A, Muñiz M, Borras J, Bargay J. Β2-Microglobulin Correlates With Bia-Muscle Mass Indexes In Newly Diagnosed Patients With Hematological Malignancies. Clin Nutr ESPEN 2023. [DOI: 10.1016/j.clnesp.2022.09.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
8
|
Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, Moissev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter P, Koreth J, Kroger N, Ljungman P, Page K, Popat U, Shaw BE, Sureda A, Soiffer R, Vasu S. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther 2023; 29:151-163. [PMID: 36442770 PMCID: PMC10119629 DOI: 10.1016/j.jtct.2022.11.015] [Citation(s) in RCA: 22] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Accepted: 11/18/2022] [Indexed: 11/27/2022]
Abstract
Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplantation (HCT) associated with significant morbidity and mortality. However, TA-TMA is a clinical diagnosis, and multiple criteria have been proposed without universal application. Although some patients have a self-resolving disease, others progress to multiorgan failure and/or death. Poor prognostic features also are not uniformly accepted. The lack of harmonization of diagnostic and prognostic markers has precluded multi-institutional studies to better understand incidence and outcomes. Even current interventional trials use different criteria, making it challenging to interpret the data. To address this urgent need, the American Society for Transplantation and Cellular Therapy, Center for International Bone Marrow Transplant Research, Asia-Pacific Blood and Marrow Transplantation, and European Society for Blood and Marrow Transplantation nominated representatives for an expert panel tasked with reaching consensus on diagnostic and prognostic criteria. The panel reviewed literature, generated consensus statements regarding diagnostic and prognostic features of TA-TMA using the Delphi method, and identified future directions of investigation. Consensus was reached on 4 key concepts: (1) TA-TMA can be diagnosed using clinical and laboratory criteria or tissue biopsy of kidney or gastrointestinal tissue; however, biopsy is not required; (2) consensus diagnostic criteria are proposed using the modified Jodele criteria with additional definitions of anemia and thrombocytopenia. TA-TMA is diagnosed when ≥4 of the following 7 features occur twice within 14 days: anemia, defined as failure to achieve transfusion independence despite neutrophil engraftment; hemoglobin decline by ≥1 g/dL or new-onset transfusion dependence; thrombocytopenia, defined as failure to achieve platelet engraftment, higher-than-expected transfusion needs, refractory to platelet transfusions, or ≥50% reduction in baseline platelet count after full platelet engraftment; lactate dehydrogenase (LDH) exceeding the upper limit of normal (ULN); schistocytes; hypertension; soluble C5b-9 (sC5b-9) exceeding the ULN; and proteinuria (≥1 mg/mg random urine protein-to-creatinine ratio [rUPCR]); (3) patients with any of the following features are at increased risk of nonrelapse mortality and should be stratified as high-risk TA-TMA: elevated sC5b-9, LDH ≥2 times the ULN, rUPCR ≥1 mg/mg, multiorgan dysfunction, concurrent grade II-IV acute graft-versus-host disease (GVHD), or infection (bacterial or viral); and (4) all allogeneic and pediatric autologous HCT recipients with neuroblastoma should be screened weekly for TA-TMA during the first 100 days post-HCT. Patients diagnosed with TA-TMA should be risk-stratified, and those with high-risk disease should be offered participation in a clinical trial for TA-TMA-directed therapy if available. We propose that these criteria and risk stratification features be used in data registries, prospective studies, and clinical practice across international settings. This harmonization will facilitate the investigation of TA-TMA across populations diverse in race, ethnicity, age, disease indications, and transplantation characteristics. As these criteria are widely used, we expect continued refinement as necessary. Efforts to identify more specific diagnostic and prognostic biomarkers are a top priority of the field. Finally, an investigation of the impact of TA-TMA-directed treatment, particularly in the setting of concurrent highly morbid complications, such as steroid-refractory GVHD and infection, is critically needed.
Collapse
Affiliation(s)
- M L Schoettler
- Department Blood and Marrow Transplantation, Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Atlanta, Georgia
| | - E Carreras
- Spanish Bone Marrow Donor Registry, Josep Carreras Foundation and Leukemia Research Institute, Barcelona, Catalunya, Spain
| | - B Cho
- Department of Internal Medicine, Catholic Blood and Marrow Transplantation Center, Seoul, Korea
| | - C E Dandoy
- Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - V T Ho
- Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
| | - S Jodele
- Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - I Moissev
- RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation
| | | | - A Srivastava
- Department of Haematology, Christian Medical College, Vellore, India
| | - Y Atsuta
- Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan
| | - P Carpenter
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - J Koreth
- Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
| | - N Kroger
- Division of Hematology, Ohio State University, Columbus, Ohio
| | - P Ljungman
- Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - K Page
- Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - U Popat
- Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - B E Shaw
- Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - A Sureda
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - R Soiffer
- Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
| | - S Vasu
- Division of Hematology, Ohio State University, Columbus, Ohio.
| |
Collapse
|
9
|
Gutiérrez-García G, Martínez C, Boumendil A, Finel H, Malladi R, Afanasyev B, Tsoulkani A, Wilson KMO, Bloor A, Nikoloudis M, Richardson D, López-Corral L, Castagna L, Cornelissen J, Giltat A, Collin M, Fanin R, Bonifazi F, Robinson S, Montoto S, Peggs KS, Sureda A. Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT. Br J Haematol 2021; 196:1018-1030. [PMID: 34750806 DOI: 10.1111/bjh.17939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 10/19/2021] [Accepted: 10/20/2021] [Indexed: 11/30/2022]
Abstract
We analysed long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation (allo-HSCT) as a first transplant for high-risk Hodgkin lymphoma (HL). One hundred and ninety patients were included in this study, 63% of them had previously received brentuximab vedotin and/or checkpoint inhibitors. Seventy patients (37%) received an unrelated donor allo-HSCT, 99 (51%) had myeloablative conditioning (MAC) and 60% had in vivo T-cell/depleted grafts (TCD). The 100-day cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 25% and the 3-year CI of chronic GVHD was 38%. The 3-year CI of non-relapse mortality (NRM) and relapse rate were 21% and 38% respectively. After a median follow-up of 58 months, 3-year overall survival (OS) and progression-free survival (PFS) were 58% and 41% respectively. Multivariate analysis showed that, in comparison to reduced-intensity conditioning regimens with or without TCD, MAC using TCD had similar NRM and a lower risk of relapse leading to significantly better OS and PFS. MAC without TCD was associated with higher NRM and worse survival outcomes. These results suggest that in patients with high-risk HL and candidates of allo-HSCT, a MAC strategy with TCD might be the best option.
Collapse
Affiliation(s)
- G Gutiérrez-García
- Department of Haematology, Bone Marrow Transplantation Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut de Recerca Biomèdica August Pi i Sunyer, Barcelona, Spain
| | - C Martínez
- Department of Haematology, Bone Marrow Transplantation Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut de Recerca Biomèdica August Pi i Sunyer, Barcelona, Spain
| | | | - H Finel
- Lymphoma Working Party, EBMT, Paris, France
| | - R Malladi
- School of Cancer Sciences, University of Birmingham, Centre for Clinical Haematology, Queen Elizabeth NHS Foundation Trust, Birmingham, UK
| | - B Afanasyev
- State Medical Pavlov University, St. Petersburg, Russia
| | | | | | - A Bloor
- Haematology and Transplant Unit, Christie Hospital NHS Foundation Trust and University of Manchester, Manchester, UK
| | - M Nikoloudis
- Haematology Department Heart of England NHS Trust, Birmingham, UK
| | - D Richardson
- Department of Haematology, Southampton General Hospital, Southampton, UK
| | | | - L Castagna
- Department of Haematology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| | - J Cornelissen
- Erasmus MC Cancer Institute University Medical Centre Rotterdam Department of Haematology, Rotterdam, Netherlands
| | - A Giltat
- Department of Haematology, Medical University Hospital, Angers, France
| | | | - R Fanin
- Department of Haematology and Cellular Therapy 'Carlo Melzi', S. Maria della Misericordia University Hospital, DAME, University of Udine, Udine, Italy
| | - F Bonifazi
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy
| | - S Robinson
- Department of Haematology and Oncology, Bristol University Hospital, Bristol, UK
| | - S Montoto
- St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - K S Peggs
- Department of Haematology, University College London Cancer Institute, London, UK
| | - A Sureda
- Clinical Department of Haematology, Institut Català d'Oncologia-Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
| |
Collapse
|
10
|
Parody R, Sánchez-Ortega I, Mussetti A, Patiño B, Arnan M, Pomares H, González-Barca E, Mercadal S, Boqué C, Maluquer C, Carro I, Peña M, Clapés V, Verdesoto S, Bustamante G, Oliveira AC, Baca C, Cabezudo E, Talarn C, Escoda L, Ortega S, García N, Isabel González-Medina M, Sánchez-Salmerón M, Fusté C, Villa J, Carreras E, Domingo-Domènech E, Sureda A. A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection. Bone Marrow Transplant 2021; 57:176-182. [PMID: 34711917 DOI: 10.1038/s41409-021-01506-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 10/04/2021] [Accepted: 10/13/2021] [Indexed: 12/11/2022]
Abstract
Traceability of patients who are candidates for Hematopoietic cell transplant (HCT) is crucial to ensure HCT program quality. Continuous knowledge of both a detailed registry from a HCT program and final exclusion causes can contribute to promoting a real-life vision and optimizing patient and donor selection. We analyzed epidemiological data reported in a 4 year-monocentric prospective registry, which included all patients presented as candidates for autologous (Auto) and/or allogeneic (Allo) HCT. A total of 543 patients were considered for HCT: 252 (42.4%) for Allo and 291 (57.6%) for Auto. A total of 98 (38.9%) patients were excluded from AlloHCT due to basal disease progression more commonly (18.2%). Seventy-six (30.2%) patients had an HLA identical sibling, whereas 147 (58.3%) patients had only Haplo. UD research was performed in 106 (42%) cases, significantly more often in myeloid than lymphoid malignancies (57% vs 28.7%, p < 0.001) but 61.3% were finally canceled, due to donor or disease causes in 72.4%. With respect to Auto candidates, a total of 60 (20.6%) patients were finally excluded; progression was the most common cause (12%). Currently, Haplo is the most frequent donor type. The high cancellation rate of UD research should be revised to optimize further donor algorithms.
Collapse
Affiliation(s)
- R Parody
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain. .,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.
| | - I Sánchez-Ortega
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,EBMT medical Office; 3. Hospital Moisès Broggi, S.Joan d'Espí, Barcelona, Spain
| | - A Mussetti
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - B Patiño
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - M Arnan
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - H Pomares
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - E González-Barca
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - S Mercadal
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - C Boqué
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - C Maluquer
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - I Carro
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - M Peña
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - V Clapés
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,H. Comarcal d'Alt Penedés, Vilafranca del Penedés, Barcelona, Spain
| | - S Verdesoto
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,EBMT medical Office; 3. Hospital Moisès Broggi, S.Joan d'Espí, Barcelona, Spain
| | - G Bustamante
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,EBMT medical Office; 3. Hospital Moisès Broggi, S.Joan d'Espí, Barcelona, Spain
| | - A C Oliveira
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Hospital Sant Camil - St. Pere de Ribes, Barcelona, Spain
| | - C Baca
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,H General de Igualada, Barcelona, Spain
| | - E Cabezudo
- EBMT medical Office; 3. Hospital Moisès Broggi, S.Joan d'Espí, Barcelona, Spain
| | - C Talarn
- Institut Català d'Oncologia-Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
| | - L Escoda
- Institut Català d'Oncologia-Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
| | - S Ortega
- Banc de Sang i Teixits, Barcelona, Barcelona, Spain
| | - N García
- Banc de Sang i Teixits, Barcelona, Barcelona, Spain
| | | | - Mar Sánchez-Salmerón
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - C Fusté
- REDMO, Fundació Josep Carreras, Barcelona, Spain
| | - J Villa
- REDMO, Fundació Josep Carreras, Barcelona, Spain
| | - E Carreras
- REDMO, Fundació Josep Carreras, Barcelona, Spain
| | - E Domingo-Domènech
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - A Sureda
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| |
Collapse
|
11
|
Capo X, Rubio M, Solomando A, Alomar C, Compa M, Sureda A, Deudero S. Microplastic intake and enzymatic responses in Mytilus galloprovincialis reared at the vicinities of an aquaculture station. Chemosphere 2021; 280:130575. [PMID: 33957472 DOI: 10.1016/j.chemosphere.2021.130575] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 04/01/2021] [Accepted: 04/09/2021] [Indexed: 06/12/2023]
Abstract
Aquaculture is a potential source of microplastics (MPs) that could be strong stressors for marine organisms. In this study, we evaluated the effects of MPs derived from aquaculture in antioxidant defences and oxidative stress markers in gills of Mytilus galloprovincialis. Mussels were distributed in three areas with different impacts: inside aquaculture cages, Control 1 (located inside Andratx harbour) and Control 2 (located in a no-anthropized area). Samples were obtained along three different time periods in May (T0), July (T60) and in September (T120). At each sampling period, mussels' biometric measurements were taken, and tissue samples were kept frozen for biochemical determinations and to determine the intake of MPs. An increase in MPs intake was detected throughout the study, and this increase was significantly higher in samples from the aquaculture cages. Similarly, antioxidant enzyme activities (catalase, superoxide dismutase, glutathione reductase and glutathione peroxidase) were significantly higher in samples from cages at T120. Additionally, a similar tendency was observed in glutathione-s-transferase, with a higher activity in the aquaculture cages at T60 and T120. Malondialdehyde and carbonyl protein derivates as a marker of oxidative damage were also measured and samples from aquaculture cages presented higher oxidative stress markers, mainly in T120. In conclusion, living in environments exposed to aquaculture activities at sea may imply a higher intake of MPs which in turn might cause an antioxidant response in M. galloprovincialis which is not enough to avoid oxidative damage.
Collapse
Affiliation(s)
- X Capo
- Instituto Español de Oceanografía, Centro Oceanografico de Baleares, Muelle de Poniente S/n, 07015, Palma de Mallorca, Balearic Islands, Spain.
| | - M Rubio
- Instituto Español de Oceanografía, Centro Oceanografico de Baleares, Muelle de Poniente S/n, 07015, Palma de Mallorca, Balearic Islands, Spain
| | - A Solomando
- Interdisciplinary Ecology Group, Department of Biology, University of the Balearic Islands, E-07122, Palma de Mallorca, Balearic Islands, Spain; Research Group in Community Nutrition and Oxidative Stress, and Health Research Institute of Balearic Islands (IdISBa), University of Balearic Islands, E-07122, Palma de Mallorca, Balearic Islands, Spain
| | - C Alomar
- Instituto Español de Oceanografía, Centro Oceanografico de Baleares, Muelle de Poniente S/n, 07015, Palma de Mallorca, Balearic Islands, Spain
| | - M Compa
- Instituto Español de Oceanografía, Centro Oceanografico de Baleares, Muelle de Poniente S/n, 07015, Palma de Mallorca, Balearic Islands, Spain
| | - A Sureda
- Research Group in Community Nutrition and Oxidative Stress, and Health Research Institute of Balearic Islands (IdISBa), University of Balearic Islands, E-07122, Palma de Mallorca, Balearic Islands, Spain; CIBEROBN (Physiopathology of Obesity and Nutrition), University of the Balearic Islands, E-07122, Palma de Mallorca, Balearic Islands, Spain
| | - S Deudero
- Instituto Español de Oceanografía, Centro Oceanografico de Baleares, Muelle de Poniente S/n, 07015, Palma de Mallorca, Balearic Islands, Spain
| |
Collapse
|
12
|
Patel M, Felip E, Sharkey R, Krengli M, Chester J, Sita-Lumsden A, Mukherjee U, Russell B, Loizidou A, Colomba J, Cruz CA, Cabirta A, Camps IR, Brunet J, Sureda A, Patriarca A, Tondini C, Pinato D, Cortellini A. 1588P SARS-CoV-2 antibody seroprevalence and safety of vaccines in cancer patients who recovered from COVID-19. Ann Oncol 2021. [PMCID: PMC8454348 DOI: 10.1016/j.annonc.2021.08.1581] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
13
|
Rovira J, González‐Barca E, M. Sancho J, Kelleher N, Rodríguez M, Fox L, Parody R, Martin S, Vicent A, Villarroel J, de la Fuente C, Ribera JM, Sureda A, Escoda L. R‐GDP SCHEDULE IN PATIENTS WITH REFRACTORY OR RELAPSED B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL). Hematol Oncol 2021. [DOI: 10.1002/hon.42_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- J Rovira
- Institut Català Oncologia, Hospital Joan XXIII Universitat Rovira i Virgili, Hematology Tarragona Spain
| | - E González‐Barca
- Institut Català Oncologia, Hospital Duran i Reynals niversitat de Barcelona, Hematology L'Hospitalet de Llobregat, Barcelona Spain
| | - J M. Sancho
- Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Hematology Badalona Spain
| | - N Kelleher
- Institut Català d'Oncologia, Hospital Trueta, Hematology Girona Spain
| | - M Rodríguez
- Institut Català d'Oncologia, Hospital Verge de la Cinta, Hematology Tortosa Spain
| | - L Fox
- Hospital Universitari Vall d'Hebron, Hematology Barcelona Spain
| | - R Parody
- Institut Català Oncologia, Hospital Duran i Reynals niversitat de Barcelona, Hematology L'Hospitalet de Llobregat, Barcelona Spain
| | - S Martin
- Institut Català Oncologia, Hospital Joan XXIII Universitat Rovira i Virgili, Hematology Tarragona Spain
| | - A Vicent
- Institut Català Oncologia, Hospital Joan XXIII Universitat Rovira i Virgili, Hematology Tarragona Spain
| | - J Villarroel
- Institut Català Oncologia, Hospital Duran i Reynals niversitat de Barcelona, Hematology L'Hospitalet de Llobregat, Barcelona Spain
| | - C de la Fuente
- Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Hematology Badalona Spain
| | - J. M Ribera
- Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Hematology Badalona Spain
| | - A Sureda
- Institut Català Oncologia, Hospital Duran i Reynals niversitat de Barcelona, Hematology L'Hospitalet de Llobregat, Barcelona Spain
| | - L Escoda
- Institut Català Oncologia, Hospital Joan XXIII Universitat Rovira i Virgili, Hematology Tarragona Spain
| |
Collapse
|
14
|
Carlo‐Stella C, Hutchings M, Offner FC, Morschhauser F, Bachy E, Crump M, Sureda A, Iacoboni G, Haioun C, Perez‐Callejo D, Lundberg L, Relf J, Clark E, Carlile D, Piccione E, Belousov A, Humphrey K, Dickinson MJ. GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS. Hematol Oncol 2021. [DOI: 10.1002/hon.15_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C Carlo‐Stella
- Humanitas University and Humanitas Research Hospital Department of Biomedical Sciences Milan Italy
| | - M Hutchings
- Rigshospitalet Department of Hematology and Phase 1 Unit Copenhagen Denmark
| | - F. C Offner
- Universitair Ziekenhuis Gent Department of Hematology Gent Belgium
| | - F Morschhauser
- Hôpital Claude Huriez and Centre Hospitalier Régional Universitaire de Lille Department of Hematology Lille France
| | - E Bachy
- Hospices Civils de Lyon and Université Claude Bernard Department of Hematology Pierre‐Bénite France
| | - M Crump
- Princess Margaret Hospital Department of Medical Oncology Toronto Canada
| | - A Sureda
- Institut Català d'Oncologia Hospitalet IDIBELL, Universitat de Barcelona Department of Clinical Haematology Barcelona Spain
| | - G Iacoboni
- Vall d’Hebron University Hospital Department of Hematology Barcelona Spain
| | - C Haioun
- Hopital Henri Mondor, AP‐HP Lymphoid Malignancies Unit Créteil France
| | - D Perez‐Callejo
- N F. Hoffmann‐La Roche Ltd Clinical Science ‐ Product Development Hematology Basel Switzerland
| | - L Lundberg
- N F. Hoffmann‐La Roche Ltd Clinical Science ‐ Product Development Hematology Basel Switzerland
| | - J Relf
- Roche Products Ltd Clinical Safety ‐ Product Development Safety Welwyn Garden City UK
| | - E Clark
- Roche Products Ltd Product Development Biostatistics Welwyn Garden City UK
| | - D Carlile
- Roche Products Ltd Clinical Pharmacology, Pharma Research and Early Development Welwyn Garden City UK
| | - E Piccione
- Genentech, Inc Oncology Biomarker Development South San Francisco USA
| | - A Belousov
- F. Hoffmann‐La Roche Ltd Product Development Biostatistics Basel Switzerland
| | - K Humphrey
- Roche Products Ltd Clinical Science ‐ Product Development Hematology Welwyn Garden City UK
| | - M. J Dickinson
- The Peter MacCallum Cancer Centre Royal Melbourne Hospital and The University of Melbourne Clinical Haematology Melbourne Australia
| |
Collapse
|
15
|
Gonzalez Barca EM, Sancho JM, Rovira J, Kelleher N, Kara M, Encuentra M, Domingo Domenech E, Oliveira AC, Ribera JM, Escoda L, Sureda A. DOUBLE‐HIT (DHL) AND TRIPLE‐HIT LYMPHOMAS (THL): REAL LIFE EXPERIENCE OF 46 CONSECUTIVE PATIENTS FROM A SINGLE INSTITUTION IN SPAIN. Hematol Oncol 2021. [DOI: 10.1002/hon.60_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. M. Gonzalez Barca
- Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - J. M. Sancho
- Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Hematology Barcelona Spain
| | - J. Rovira
- Institut Català d'Oncologia, Hospital Universitari Joan XXIII, Hematology Tarragona Spain
| | - N. Kelleher
- Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - M. Kara
- Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - M. Encuentra
- Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - E. Domingo Domenech
- Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - A. C. Oliveira
- Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - J. M. Ribera
- Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Hematology Barcelona Spain
| | - L. Escoda
- Institut Català d'Oncologia, Hospital Universitari Joan XXIII, Hematology Tarragona Spain
| | - A. Sureda
- Institut Català d'Oncologia, Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Hematology Girona Spain
| |
Collapse
|
16
|
Dreger P, Ngoya M, Litovich C, Finel H, Herrera AF, Sauter C, Kharfan‐Dabaja M, Sureda A, Blaise D, Castagna L, Corradini P, Pastano R, Arat M, Boumendil A, Dietrich S, Schmitz N, Glass B, Montoto S, Hamadani M. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T‐CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLO‐IDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSIS. Hematol Oncol 2021. [DOI: 10.1002/hon.53_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Dreger
- EBMT Lymphoma Working Party Paris France
| | - M. Ngoya
- EBMT Lymphoma Working Party Paris France
| | - C. Litovich
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | - H. Finel
- EBMT Lymphoma Working Party Paris France
| | - A. F Herrera
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | - C. Sauter
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | | | - A. Sureda
- EBMT Lymphoma Working Party Paris France
| | - D. Blaise
- EBMT Lymphoma Working Party Paris France
| | | | | | - R. Pastano
- EBMT Lymphoma Working Party Paris France
| | - M. Arat
- EBMT Lymphoma Working Party Paris France
| | | | | | - N. Schmitz
- EBMT Lymphoma Working Party Paris France
| | - B. Glass
- EBMT Lymphoma Working Party Paris France
| | - S. Montoto
- EBMT Lymphoma Working Party Paris France
| | - M. Hamadani
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| |
Collapse
|
17
|
Gallamini A, Walewski J, Rambaldi A, Viviani S, Sureda A, André M, Rossi C, Moccia A, Zucca E, Rossi D, Filippi A, Meignan M, Chauvie S, Zaucha JM. RADIATION FREE THERAPY OR THE INITIAL TREATMENT OF GOOD PROGNOSIS EARLY NON‐BULKY HODGKIN LYMPHOMA, DEFINED BY A LOW METABOLIC TUMOR VOLUME AND A NEGATIVE PET‐2 ‐ RAFTING TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.158_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Gallamini
- Antoine Lacassagne Cancer Center Research and Clinical Innovation Nice France
| | - J. Walewski
- Marii Skłodowskiej‐Curie Institute Onco‐Hematology Warsaw Poland
| | - A. Rambaldi
- Ospedale Papa Giovanni XXIII Hematology Bergamo Italy
| | - S. Viviani
- Istituto Europeo di Ematologia Hematology Milano Italy
| | - A. Sureda
- Institut Català d'Oncologia Hematology Barcelona Spain
| | - M. André
- Cliniques universitaires Saint‐Luc ‐ UC Louvain Hematology Louvain Belgium
| | - C. Rossi
- CHU Bocage Hematology Dijon France
| | - A. Moccia
- Istituto Oncologico della Svizzera Italiana Hematology Bellinzona Switzerland
| | - E. Zucca
- Istituto Oncologico della Svizzera Italiana Hematology Bellinzona Switzerland
| | - D. Rossi
- Istituto Oncologico della Svizzera Italiana Hematology Bellinzona Switzerland
| | - A. Filippi
- Policlinico S. Matteo IRCCS Radiation Oncology Pavia Italy
| | - M. Meignan
- Henry Mondor Hospital LYSA Imaging Paris France
| | - S. Chauvie
- Ospedale S. Croce e Carle Medical Physics Cuneo Italy
| | - J. M. Zaucha
- Medical University of Gdansk Hematology Gdansk Poland
| |
Collapse
|
18
|
Villarreal JA, Rovira J, Franch M, Encuentra M, Blazevic D, Rodriguez M, Kelleger N, Martín S, Oliveira AC, Domingo Domenech E, Ribera JM, Sureda A, Sancho JM, Escoda L, González‐Barca E. INTRAVENOUS HIGH DOSE METHOTREXATE AS CENTRAL NERVOUS SYSTEM (CNS) PROPHYLAXIS IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) WITH HIGH RISK FOR CNS PROGRESSION. Hematol Oncol 2021. [DOI: 10.1002/hon.46_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. A. Villarreal
- Institut Català d'Oncologia Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - J. Rovira
- nstitut Català d'Oncologia Hospital Universitari Joan XXIII, Hematology Tarragona Spain
| | - M. Franch
- Institut Català d'Oncologia Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras Universitat Autònoma de Barcelona Hematology Badalona Barcelona Spain
| | - M. Encuentra
- Institut Català d'Oncologia Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - D. Blazevic
- Institut Català d'Oncologia Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - M. Rodriguez
- Institut Català d'Oncologia Hospital de Tortosa Verge de la Cinta Hematology Tortosa Tarragona Spain
| | - N. Kelleger
- Institut Català d'Oncologia Hospital Universitari de Girona Doctor Josep Truet Institut d'Investigació Biomèdica de Girona (IDIBGI) Universitat de Girona Hematology Girona Spain
| | - S. Martín
- nstitut Català d'Oncologia Hospital Universitari Joan XXIII, Hematology Tarragona Spain
| | - A. C. Oliveira
- Institut Català d'Oncologia Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - E. Domingo Domenech
- Institut Català d'Oncologia Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - J. M. Ribera
- Institut Català d'Oncologia Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras Universitat Autònoma de Barcelona Hematology Badalona Barcelona Spain
| | - A. Sureda
- Institut Català d'Oncologia Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Hematology L'Hospitalet de Llobregat Barcelona Spain
| | - J. M. Sancho
- Institut Català d'Oncologia Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras Universitat Autònoma de Barcelona Hematology Badalona Barcelona Spain
| | - L. Escoda
- nstitut Català d'Oncologia Hospital Universitari Joan XXIII, Hematology Tarragona Spain
| | - E. González‐Barca
- Institut Català d'Oncologia Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Hematology L'Hospitalet de Llobregat Barcelona Spain
| |
Collapse
|
19
|
Franch‐Sarto M, Garcia‐Calduch O, Rivas A, Lopez A, Gonzalez‐Barca E, Sureda A, Baile M, Martin A, Salar A, Gutierrez A, Bastos M, Rodriguez M, Gonzalez S, Queizán J, Cordoba R, Montalbán C, Luzardo HD, Abrisqueta P, Garcia D, Hong A, Peñalver F, Moreno M, Sancho J. CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH R‐CHOP: STUDY OF THE SPANISH LYMPHOMA GROUP GELTAMO. Hematol Oncol 2021. [DOI: 10.1002/hon.91_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Franch‐Sarto
- Hospital Universitari Germans Trias i Pujol Hematology Badalona Spain
| | - O. Garcia‐Calduch
- Hospital Universitari Germans Trias i Pujol Hematology Badalona Spain
| | - A. Rivas
- Hospital Universitari Clinic Hematology Barcelona Spain
| | - A. Lopez
- Hospital Universitari Clinic Hematology Barcelona Spain
| | | | - A. Sureda
- Hospital Duran i Reynalds Hematology Bellvitge Spain
| | - M. Baile
- Hospital Universitario de Salamanca and IBSAL. Hematology Salamanca Spain
| | - A. Martin
- Hospital Universitario de Salamanca and IBSAL. Hematology Salamanca Spain
| | - A. Salar
- Hospital del Mar Hematology Barcelona Spain
| | | | - M. Bastos
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - M.‐J. Rodriguez
- Hospital Universitario de Canarias Hematology Canarias Spain
| | - S. Gonzalez
- Hospital Universitario Marqués de Valdecilla Hematology Santander Spain
| | - J.‐A. Queizán
- Hospital General de Segovia Hematology Segovia Spain
| | - R. Cordoba
- Fundación Jiméndez Díaz Hematology Madrid Spain
| | - C. Montalbán
- MD Anderson Cancer Center Hematology Madrid Spain
| | - H. D. Luzardo
- Hospital Universitario de Gran Canarias Dr Negrín Hematology Las Palmas de Gran Canaria Spain
| | - P. Abrisqueta
- Hospital Universitari Vall d'Hebron Hematology Barcelona Spain
| | - D. Garcia
- Hospital La Zarzuela Hematology Madrid Spain
| | - A. Hong
- Hospital de Lanzarote Hematology Lanzarote Spain
| | | | - M. Moreno
- Hospital Universitari Germans Trias i Pujol Hematology Badalona Spain
| | - J.‐M. Sancho
- Hospital Universitari Germans Trias i Pujol Hematology Badalona Spain
| |
Collapse
|
20
|
Domingo Domenech E, Sancho Cia JM, Gonzalez Barca E, Kelleher N, Rodriguez‐Luaces M, Rovira J, Verdesoto S, Encuentra M, Blazevic D, Oliveira A, Escoda L, Ribera JM, Sureda A. BRENTUXIMAB VEDOTIN PLUS CHP AS FIRST‐LINE TREATMENT IN CD30 + PERIPHERAL T‐CELL LYMPHOMAS: REAL LIFE EXPERIENCE FROM A SINGLE INSTITUTION IN SPAIN. Hematol Oncol 2021. [DOI: 10.1002/hon.73_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. Domingo Domenech
- Institut Català d’Oncologia Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) Universitat de Barcelona Hematology L’Hospitalet de Llobregat Barcelona Spain
| | - J. M. Sancho Cia
- Institut Català d’Oncologia Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras Universitat Autònoma de Barcelona, Badalona, Barcelona,Spain Hematology Badalona Spain
| | - E. Gonzalez Barca
- Institut Català d’Oncologia Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) Universitat de Barcelona Hematology L’Hospitalet de Llobregat Barcelona Spain
| | - N. Kelleher
- Institut Català d’Oncologia Institut d'Investigació Biomèdica de Girona (IDIBGI) Universitat de Girona Hematology Girona Spain
| | - M. Rodriguez‐Luaces
- Institut Català d’Oncologia Hospital de Tortosa Verge de la Cinta Hematology Tortosa Spain
| | - J. Rovira
- Institut Català d’Oncologia Hospital Universitari Joan XXIII Hematology Tarragona Spain
| | - S. Verdesoto
- Institut Català d’Oncologia Hospital Moises Broggi Hematology, Sant Joan d’Espí Barcelona Spain
| | - M. Encuentra
- Institut Català d’Oncologia Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) Universitat de Barcelona Hematology L’Hospitalet de Llobregat Barcelona Spain
| | - D. Blazevic
- Institut Català d’Oncologia Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) Universitat de Barcelona Hematology L’Hospitalet de Llobregat Barcelona Spain
| | - A. Oliveira
- Institut Català d’Oncologia Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) Universitat de Barcelona Hematology L’Hospitalet de Llobregat Barcelona Spain
| | - L. Escoda
- Institut Català d’Oncologia Hospital Universitari Joan XXIII Hematology Tarragona Spain
| | - J. M. Ribera
- Institut Català d’Oncologia Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras Universitat Autònoma de Barcelona, Badalona, Barcelona,Spain Hematology Badalona Spain
| | - A. Sureda
- Institut Català d’Oncologia Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) Universitat de Barcelona Hematology L’Hospitalet de Llobregat Barcelona Spain
| |
Collapse
|
21
|
Capó X, Company JJ, Alomar C, Compa M, Sureda A, Grau A, Hansjosten B, López-Vázquez J, Quintana JB, Rodil R, Deudero S. Long-term exposure to virgin and seawater exposed microplastic enriched-diet causes liver oxidative stress and inflammation in gilthead seabream Sparus aurata, Linnaeus 1758. Sci Total Environ 2021; 767:144976. [PMID: 33636779 DOI: 10.1016/j.scitotenv.2021.144976] [Citation(s) in RCA: 59] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Revised: 12/27/2020] [Accepted: 12/30/2020] [Indexed: 06/12/2023]
Abstract
Plastics accumulation in marine ecosystems has notable ecological implications due to their long persistence, potential ecotoxicity, and ability to adsorb other pollutants or act as vectors of pathogens. The present work aimed to evaluate the physiological response of the gilthead seabream (Sparus aurata) fed for 90 days with a diet enriched with virgin and seawater exposed low-density polyethylene microplastics (LDPE-MPs) (size between 100 and 500 μM), followed by 30 days of depuration, applying oxidative stress and inflammatory markers in liver homogenates. No effects of LDPE-MPs treatments on fish growth were observed throughout this study. A progressive increase in antioxidant enzyme activities was observed throughout the study in both treatments, although this increase was higher in the group treated with seawater exposed MPs. This increase was significantly higher in catalase (CAT), glutathione reductase (GRd), and glutathione-s-transferase (GST) in the seawater exposed MPs group, with respect to the virgin group. In contrast, no significant differences were recorded in superoxide dismutase (SOD) and glutathione peroxidase (GPx) between both groups. Exposure to MPs also caused an increase in the oxidative damage markers (malondialdehyde and carbonyls groups). Myeloperoxidase activity significantly increased because of MPs treatments. After 30 days of depuration, antioxidant, inflammatory enzyme activities and oxidative damage markers returned to values similar to those observed in the control group. In conclusion, MPs exposure induced an increase of antioxidant defences in the liver of S. aurata. However, these elevated antioxidant capabilities were not enough to prevent oxidative damage in the liver since, an increased oxidative damage marker was associated with MPs ingestion. The treatment with seawater exposed MPs caused a more significant antioxidant response (CAT, GRs, and GST). Although after a depuration period of 30 days a tendency to recover the initial values of the biomarkers was observed this does not seem to be time enough for a complete normalization.
Collapse
Affiliation(s)
- X Capó
- Instituto Español de Oceanografía, Centro Oceanografico de Baleares, Muelle de Poniente s/n, 07015 Palma de Mallorca, Balearic Islands, Spain.
| | - J J Company
- Instituto Español de Oceanografía, Centro Oceanografico de Baleares, Muelle de Poniente s/n, 07015 Palma de Mallorca, Balearic Islands, Spain
| | - C Alomar
- Instituto Español de Oceanografía, Centro Oceanografico de Baleares, Muelle de Poniente s/n, 07015 Palma de Mallorca, Balearic Islands, Spain
| | - M Compa
- Instituto Español de Oceanografía, Centro Oceanografico de Baleares, Muelle de Poniente s/n, 07015 Palma de Mallorca, Balearic Islands, Spain
| | - A Sureda
- Research Group in Community Nutrition and Oxidative Stress, and Health Research Institute of Balearic Islands (IdISBa), University of Balearic Islands, E-07122 Palma de Mallorca, Balearic Islands, Spain; CIBER (Fisiopatologia de la obesidad y nutrición) CIBEROBN. Instituto de Salud Carlos III, (ISCIII), 28029 Madrid, Spain
| | - A Grau
- Laboratorio de Investigaciones Marinas y Acuicultura, LIMIA-Govern de les Illes Balears, Port d'Andratx, Balearic Islands, Spain
| | - B Hansjosten
- Laboratorio de Investigaciones Marinas y Acuicultura, LIMIA-Govern de les Illes Balears, Port d'Andratx, Balearic Islands, Spain
| | - J López-Vázquez
- Department of Analytical Chemistry, Nutrition and Food Sciences, Institute of Research on Chemical and Biological Analysis (IAQBUS), Universidad de Santiago de Compostela, Constantino Candeira S/N, 15782 Santiago de Compostela, Spain
| | - J B Quintana
- Department of Analytical Chemistry, Nutrition and Food Sciences, Institute of Research on Chemical and Biological Analysis (IAQBUS), Universidad de Santiago de Compostela, Constantino Candeira S/N, 15782 Santiago de Compostela, Spain
| | - R Rodil
- Department of Analytical Chemistry, Nutrition and Food Sciences, Institute of Research on Chemical and Biological Analysis (IAQBUS), Universidad de Santiago de Compostela, Constantino Candeira S/N, 15782 Santiago de Compostela, Spain
| | - S Deudero
- Instituto Español de Oceanografía, Centro Oceanografico de Baleares, Muelle de Poniente s/n, 07015 Palma de Mallorca, Balearic Islands, Spain
| |
Collapse
|
22
|
Moreno-González G, Mussetti A, Albasanz-Puig A, Salvador I, Sureda A, Gudiol C, Salazar R, Marin M, Garcia M, Navarro V, de la Haba Vaca I, Coma E, Sanz-Linares G, Dura X, Fontanals S, Serrano G, Cruz C, Mañez R. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Trials 2021; 22:116. [PMID: 33546739 PMCID: PMC7862837 DOI: 10.1186/s13063-021-05072-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Accepted: 01/24/2021] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVES Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the Januse-Kinase signalling transducer and activator of transcription (JAK-STAT) pathway. Moreover, it reduces the receptor mediated viral endocytosis by AP2-associated protein kinase 1 (AAK1) inhibition. We propose the use of baricinitib to prevent the progression of the respiratory insufficiency in SARS-CoV2 pneumonia in onco-haematological patients. In this phase Ib/II study, the primary objective in the safety cohort is to describe the incidence of severe adverse events associated with baricitinib administration. The primary objective of the randomized phase (baricitinib cohort versus standard of care cohort) is to evaluate the number of patients who did not require mechanical oxygen support since start of therapy until day +14 or discharge (whichever it comes first). The secondary objectives of the study (only randomized phase of the study) are represented by the comparison between the two arms of the study in terms of mortality and toxicity at day+30. Moreover, a description of the immunological related changes between the two arms of the study will be reported. TRIAL DESIGN The trial is a phase I/II study with a safety run-in cohort (phase 1) followed by an open label phase II randomized controlled trial with an experimental arm compared to a standard of care arm. PARTICIPANTS The study will be performed at the Institut Català d'Oncologia, a tertiary level oncological referral center in the Catalonia region (Spain). The eligibility criteria are: patients > 18 years affected by oncological diseases; ECOG performance status < 2 (Karnofsky score > 60%); a laboratory confirmed infection with SARS-CoV-2 by means of real -time PCR; radiological signs of low respiratory tract disease; absence of organ dysfunction (a total bilirubin within normal institutional limits, AST/ALT≤2.5 X institutional upper limit of normal, alkaline phosphatase ≤2.5 X institutional upper limit of normal, coagulation within normal institutional limits, creatinine clearance >30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal); absence of HIV infection; no active or latent HBV or HCV infection. The exclusion criteria are: patients with oncological diseases who are not candidates to receive any active oncological treatment; hemodynamic instability at time of study enrollment; impossibility to receive oral medication; medical history of recent or active pulmonary embolism or deep venous thrombosis or patients at high-risk of suffering them (surgical intervention, immobilization); multi organ failure, rapid worsening of respiratory function with requirement of fraction of inspired oxygen (FiO2) > 50% or high-flow nasal cannula before initiation of study treatment; uncontrolled intercurrent illness (ongoing or severe active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements); allergy to one or more of study treatments; pregnant or breastfeeding women; positive pregnancy test in a pre-dose examination. Patients should have the ability to understand, and the willingness to sign, a written informed consent document; the willingness to accept randomization to any assigned treatment arm; and must agree not to enroll in another study of an investigational agent prior to completion of Day +28 of study. An electronic Case Report Form in the Research Electronic Data Capture (REDCap) platform will be used to collect the data of the trial. Removal from the study will apply in case of unacceptable adverse event(s), development of an intercurrent illness, condition or procedural complication, which could interfere with the patient's continued participation and voluntary patient withdrawal from study treatment (all patients are free to withdraw from participation in this study at any time, for any reasons, specified or unspecified, and without prejudice). INTERVENTION AND COMPARATOR Treatment will be administered on an inpatient basis. We will compare the experimental treatment with baricitinib plus the institutional standard of care compared with the standard of care alone. During the phase I, we will define the dose-limiting toxicity of baricitinib and the dose to be used in the phase 2 part of the study. The starting baricitinib dose will be an oral tablet 4 mg-once daily which can be reduced to 2 mg depending on the observed toxicity. The minimum duration of therapy will be 5 days and it can be extended to 7 days. The standard of care will include the following therapies. Antibiotics will be individualized based on clinical suspicion, including the management of febrile neutropenia. Prophylaxis of thromboembolic disease will be administered to all participants. Remdesivir administration will be considered only in patients with severe pneumonia (SatO2 <94%) with less than 7 days of onset of symptoms and with supplemental oxygen requirements but not using high-flow nasal cannula, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). In the randomized phase, tocilizumab or interferon will not be allowed in the experimental arm. Tocilizumab can be used in patients in the standard of care arm at the discretion of the investigator. If it is prescribed it will be used according to the following criteria: patients who, according to his baseline clinical condition, would be an ICU tributary, interstitial pneumonia with severe respiratory failure, patients who are not on mechanical ventilation or ECMO and who are still progressing with corticoid treatment or if they are not candidates for corticosteroids. Mild ARDS (PAFI <300 mmHg) with radiological or blood gases deterioration that meets at least one of the following criteria: CRP >100mg/L D-Dimer >1,000μg/L LDH >400U/L Ferritin >700ng/ml Interleukin 6 ≥40ng/L. The use of tocilizumab is not recommended if there are AST/ALT values greater than 10 times the upper limit of normal, neutrophils <500 cells/mm3, sepsis due to other pathogens other than SARS-CoV-2, presence of comorbidity that can lead to a poor prognosis, complicated diverticulitis or intestinal perforation, ongoing skin infection. The dose will be that recommended by the Spanish Medicine Agency in patients ≥75Kg: 600mg dose whereas in patients <75kg: 400mg dose. Exceptionally, a second infusion can be assessed 12 hours after the first in those patients who experience a worsening of laboratory parameters after a first favourable response. The use of corticosteroids will be recommended in patients who have had symptoms for more than 7 days and who meet all the following criteria: need for oxygen support, non-invasive or invasive mechanical ventilation, acute respiratory failure or rapid deterioration of gas exchange, appearance or worsening of bilateral alveolar-interstitial infiltrates at the radiological level. In case of indication, it is recommended: dexamethasone 6mg/d p.o. or iv for 10 days or methylprednisolone 32mg/d orally or 30mg iv for 10 days or prednisone 40mg day p.o. for 10 days. MAIN OUTCOMES Phase 1 part: to describe the toxicity profile of baricitinib in COVID19 oncological patients during the 5-7 day treatment period and until day +14 or discharge (whichever it comes first). Phase 2 part: to describe the number of patients in the experimental arm that will not require mechanical oxygen support compared to the standard of care arm until day +14 or discharge (whichever it comes first). RANDOMISATION For the phase 2 of the study, the allocation ratio will be 1:1. Randomization process will be carried out electronically through the REDcap platform ( https://www.project-redcap.org/ ) BLINDING (MASKING): This is an open label study. No blinding will be performed. NUMBERS TO BE RANDOMISED (SAMPLE SIZE) The first part of the study (safety run-in cohort) will consist in the enrollment of 6 to 12 patients. In this population, we will test the toxicity of the experimental treatment. An incidence of severe adverse events grade 3-4 (graded by Common Terminology Criteria for Adverse Events v.5.0) inferior than 33% will be considered sufficient to follow with the next part of the study. The second part of the study we will perform an interim analysis of efficacy at first 64 assessed patients and a definitive one will analyze 128 assessed patients. Interim and definitive tests will be performed considering in both cases an alpha error of 0.05. We consider for the control arm this rate is expected to be 0.60 and for the experimental arm of 0.80. Considering this data, a superiority test to prove a difference of 0.20 with an overall alpha error of 0.10 and a beta error of 0.2 will be performed. Considering a 5% of dropout rate, it is expected that a total of 136 patients, 68 for each study arm, will be required to complete study accrual. TRIAL STATUS Version 5.0. 14th October 2020 Recruitment started on the 16th of December 2020. Expected end of recruitment is June 2021. TRIAL REGISTRATION AEMPs: 20-0356 EudraCT: 2020-001789-12, https://www.clinicaltrialsregister.eu/ctr-search/search (Not publically available as Phase I trial) Clinical trials: BARCOVID19, https://www.clinicaltrials.gov/ (In progress) FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol."
Collapse
Affiliation(s)
- G Moreno-González
- Intensive Care Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain. .,Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.
| | - A Mussetti
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Clinical Hematology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - A Albasanz-Puig
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.,Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain
| | - I Salvador
- Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain
| | - A Sureda
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Clinical Hematology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.,Barcelona University, Barcelona, Spain
| | - C Gudiol
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.,Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain.,Barcelona University, Barcelona, Spain
| | - R Salazar
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Clinical Oncology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - M Marin
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Clinical Oncology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - M Garcia
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Clinical Trials Unit, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - V Navarro
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Clinical Trials Unit, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - I de la Haba Vaca
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Oncology Emergency Unit, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - E Coma
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Oncology Emergency Unit, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - G Sanz-Linares
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Clinical Hematology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - X Dura
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain
| | - S Fontanals
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Pharmacology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - G Serrano
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Palliative Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - C Cruz
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.,Palliative Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain
| | - R Mañez
- Intensive Care Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain
| |
Collapse
|
23
|
Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, Arcese W, Browne P, Beelen D, Kobbe G, Veelken H, Arranz R, Greinix H, Lenhoff S, Poiré X, Ribera JM, Thompson J, Zuckerman T, Mufti GJ, Cortelezzi A, Olavarria E, Dreger P, Sureda A, Montoto S. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2021; 56:1391-1401. [PMID: 33420392 DOI: 10.1038/s41409-020-01197-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 10/05/2020] [Accepted: 12/09/2020] [Indexed: 12/30/2022]
Abstract
BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option in advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS). This study presents an updated analysis of the initial experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) describing the outcomes after allo-HSCT for MF and SS, with special emphasis on the impact of the use of unrelated donors (URD). METHODS AND PATIENTS Eligible for this study were patients with advanced-stage MF or SS who underwent a first allo-HSCT from matched HLA-identical related or URD between January/1997 and December/2011. Sixty patients have been previously reported. RESULTS 113 patients were included [77 MF (68%)]; 61 (54%) were in complete or partial remission, 86 (76%) received reduced-intensity protocols and 44 (39%) an URD allo-HSCT. With a median follow up for surviving patients of 73 months, allo-HSCT resulted in an estimated overall survival (OS) of 38% at 5 years, and a progression-free survival (PFS) of 26% at 5 years. Multivariate analysis demonstrated that advanced-phase disease (complete remission/partial remission >3, primary refractory or relapse/progression in patients that had received 3 or more lines of systemic treatment prior to transplant or the number of treatment lines was not known), a short interval between diagnosis and transplant (<18 months) were independent adverse prognostic factors for PFS; advanced-phase disease and the use of URDs were independent adverse prognostic factors for OS. CONCLUSIONS This extended series supports that allo-HSCT is able to effectively rescue over one third of the population of patients with advanced-stage MF/SS. High relapse rate is still the major cause of failure and needs to be improved with better strategies before and after transplant. The negative impact of URD is a matter of concern and needs to be further elucidated in future studies.
Collapse
Affiliation(s)
- E Domingo-Domenech
- Hematology Department, Institut Català d'Oncologia. Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
| | - R F Duarte
- Hematology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | - A Boumedil
- EBMT Central Registry Office, Paris, France
| | - F Onida
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico IRCCS, Milano, Italy
| | - I Gabriel
- Department of Hematology, Imperial College, Hammersmith Hospital, London, United Kingdom
| | - H Finel
- EBMT Central Registry Office, Paris, France
| | - W Arcese
- Tor Vergata University of Rome, Stem Cell Transplant Unit, Policlinico Universitario Tor Vergata, Rome, Italy
| | - P Browne
- St's James Hospital, Dublin, Ireland
| | - D Beelen
- University Hospital, Department of Bone Marrow Transplantation, Essen, Germany
| | - G Kobbe
- Heinrich Heine University, Medical F, Department of Hematology, Düsseldorf, Germany
| | - H Veelken
- Leiden University Medical Center, Leiden, The Netherlands
| | - R Arranz
- Hematology Department, Hospital La Princesa, Madrid, Spain
| | - H Greinix
- Division of Hematology, Medical University Graz, Graz, Austria
| | - S Lenhoff
- Skanes University Hospital, Department of Hematology, Lund, Sweden
| | - X Poiré
- Cliniques Universitaires St. Luc, Department of Hematology, Brussels, Belgium
| | - J M Ribera
- Hematology Department, Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, Badalona, Spain
| | - J Thompson
- Albert's Stem Cell Transplantation Center, Pretoria, South Africa
| | - T Zuckerman
- Ramban Medical Center, Department of Hematology and Bone Marrow Transplantation, Haifa, Israel
| | - G J Mufti
- GKT School of Medicine, Dept. of Haematological Medicine, King's Denmark Hill Campus, London, United Kingdom
| | - A Cortelezzi
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico IRCCS, Milano, Italy
| | - E Olavarria
- Department of Hematology, Imperial College, Hammersmith Hospital, London, United Kingdom
| | - P Dreger
- Universitaetsklinkum Heidelberg, Heidelberg, Germany
| | - A Sureda
- Hematology Department, Institut Català d'Oncologia. Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain
| | - S Montoto
- Department of Haemato-Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
| |
Collapse
|
24
|
Sureda A, Monserrat-Mesquida M, Pinya S, Ferriol P, Tejada S. Hypotensive effects of the triterpene oleanolic acid for cardiovascular prevention. Curr Mol Pharmacol 2020; 14:935-942. [PMID: 33390142 DOI: 10.2174/1874467213999201230211544] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Revised: 12/15/2019] [Accepted: 07/20/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Hypertension is a high prevalent chronic disease worldwide and a major cardiovascular risk factor. Oleanolic acid (3β-hydroxy-olea-12-en-28-oic acid) is a wide distributed bioactive pentacyclic triterpenoid with diverse biological activities such as anti-inflammatory, hepaprotective anti-diabetic or anti-hypertensive. OBJECTIVE The aim of this study was to review and highlight the available data about antihypertensive activity of oleanolic acid and the described mechanisms of action. METHOD Extensive searches were made in the available literature on oleanolic acid and the data investigating its antihypertensive effects were analysed. RESULTS Most of research has been performed on animal models of hypertension, ex vivo studies with aortic ring and some in vitro tests with cell cultures, whereas clinical trials are still lacking. Treatment of hypertensive animals with oleanolic acid significantly ameliorated the rise in the systolic blood pressure. In addition, the hypotensive effects of oleanolic acid are also related to a potent diuretic-natriuretic activity and nephroprotection. In vitro studies have characterized the participation of various signalling pathways that modulate the release of vasodilation mediators. CONCLUSION In vitro and in vivo studies suggest that oleanolic acid effectively reduce blood pressure and could be an interesting co-adjuvant to conventional treatment of hypertension.
Collapse
Affiliation(s)
- A Sureda
- Research Group on Community Nutrition and Oxidative Stress (NUCOX), Department of Fundamental Biology and Health Sciences and CIBEROBN (Physiopathology of Obesity and Nutrition CB12/03/30038), University of the Balearic Islands,. Spain
| | - M Monserrat-Mesquida
- Research Group on Community Nutrition and Oxidative Stress (NUCOX), Department of Fundamental Biology and Health Sciences and CIBEROBN (Physiopathology of Obesity and Nutrition CB12/03/30038), University of the Balearic Islands,. Spain
| | - S Pinya
- Interdisciplinary Ecology Group, Department of Biology, University of the Balearic Islands,. Spain
| | - P Ferriol
- Interdisciplinary Ecology Group, Department of Biology, University of the Balearic Islands,. Spain
| | - S Tejada
- Laboratory of Neurophysiology, Department of Biology and CIBEROBN (Physiopathology of Obesity and Nutrition CB12/03/30038), University of the Balearic Islands. Spain
| |
Collapse
|
25
|
Capó X, Tejada S, Ferriol P, Pinya S, Mateu-Vicens G, Montero-González I, Box A, Sureda A. Hypersaline water from desalinization plants causes oxidative damage in Posidonia oceanica meadows. Sci Total Environ 2020; 736:139601. [PMID: 32485379 DOI: 10.1016/j.scitotenv.2020.139601] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/18/2020] [Revised: 05/19/2020] [Accepted: 05/19/2020] [Indexed: 05/11/2023]
Abstract
Posidonia oceanica is an endemic marine phanerogam of the Mediterranean Sea for that is very sensitive to the environmental changes, especially those related to human activities. The aim of this study was to evaluate the oxidative stress status of P. oceanica meadows exposed to spillage of hypersaline water from a desalination station by using biomarkers. Leaf samples of P. oceanica were obtained from 4 different points exposed to different levels of salinity water. Samples from the area with the highest salinity conditions were 75% shorter than the samples from the control area. Exposure to high salinity induced an increase in the levels of oxidative stress markers (malondialdehyde (MDA) and protein carbonyls). Interestingly, in the area with the highest salinity the activities of glutathione peroxidase, glutathione reductase and glutathione-s-transferase were significantly induced respect to the other studies areas, while catalase (CAT) and superoxide dismutase (SOD) activities were lower. In addition, salinity induced a progressive increase in non-enzymatic antioxidants (polyphenols and glutathione) and in total antioxidant capacity reaching the highest concentrations in samples directly affected by the saline discharge. In conclusion chronic exposure to high salinity induced an increase in total antioxidant capacity in P. oceanica. However, this increase was not enough to protect the plant against oxidative stress as it is evidenced by the raise in oxidative stress markers. The obtained data suggest that high salinity conditions deactivated CAT and SOD antioxidant enzymes and caused an increase in non-enzymatic antioxidants (polyphenols and glutathione) and in glutathione-related enzymes.
Collapse
Affiliation(s)
- X Capó
- Research Group on Community Nutrition and Oxidative Stress (NUCOX), University of Balearic Islands, E-07122 Palma de Mallorca, Balearic Islands, Spain; Instituto Español de Oceanografía, Centro Oceanográfico de Baleares, Muelle de Poniente s/n, 07015 Palma de Mallorca, Balearic Islands, Spain.
| | - S Tejada
- CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122 Palma de Mallorca, Balearic Islands, Spain; Department of Biology, Laboratory of Neurophysiology, University of Balearic Islands, Spain
| | - P Ferriol
- Interdisciplinary Ecology Group, Biology Department, University of the Balearic Islands, E-07122 Palma de Mallorca, Spain
| | - S Pinya
- Interdisciplinary Ecology Group, Biology Department, University of the Balearic Islands, E-07122 Palma de Mallorca, Spain; Museu Balear de Ciències Naturals, Ctra. Palma - Port de Sóller km 30, 07100 Sóller, Balearic Islands, Spain
| | - G Mateu-Vicens
- Interdisciplinary Ecology Group, Biology Department, University of the Balearic Islands, E-07122 Palma de Mallorca, Spain; Museu Balear de Ciències Naturals, Ctra. Palma - Port de Sóller km 30, 07100 Sóller, Balearic Islands, Spain; Laboratory of Zoology, Biology Department, University of the Balearic Islands, E-07122 Palma de Mallorca, Spain
| | - I Montero-González
- Department of Biotechnology, University of Alicante, Alicante E-03690, Spain
| | - A Box
- Consell Insular d'Eivissa, Dep. Agricultura, Ramaderia, Pesca, Caça i Cooperació Municipal, Av. Espanya n°49, CP 07800 Ibiza, Balearic Islands, Spain
| | - A Sureda
- Research Group on Community Nutrition and Oxidative Stress (NUCOX), University of Balearic Islands, E-07122 Palma de Mallorca, Balearic Islands, Spain; CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122 Palma de Mallorca, Balearic Islands, Spain
| |
Collapse
|
26
|
Soosaipillai G, Sureda A, Maluquer Artigal C, Benafif S, Chopra N, Harbeck N, Wuerstlein R, Mesia Nin R, Felip E, Ottaviani D, Galazi M, Lee A, Salazar R, Sharkey R, Reyes R, Evans J, Carmona Garcia M, Tabernero J, Prat A, Pinato D. 1671MO Provision of palliative care for patients with cancer and SARS-CoV-2 infection. Ann Oncol 2020. [PMCID: PMC7506333 DOI: 10.1016/j.annonc.2020.08.1736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Capó X, Ferrer MD, Olek RA, Salaberry E, Gomila RM, Martorell G, Sureda A, Tur JA, Pons A. Simultaneous analysis of saturated and unsaturated oxylipins in 'ex vivo' cultured peripheral blood mononuclear cells and neutrophils. J Pharm Biomed Anal 2020; 186:113258. [PMID: 32294601 DOI: 10.1016/j.jpba.2020.113258] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Revised: 03/06/2020] [Accepted: 03/12/2020] [Indexed: 12/31/2022]
Abstract
Oxylipins are a family of saturated and unsaturated fatty acids peroxidation products with bioactive properties. We have developed an improved method for the measurement of ex vivo oxylipin production by peripheral blood mononuclear cells (PBMCs) and neutrophils. We aimed to develop an analytical method to determine the production rates of polyunsaturated fatty acids (PUFAs), PUFA-oxylipin, and saturated-oxylipins by stimulated PBMCs and neutrophils based on solid phase extraction and HPLC-MS/MS technology. A UHPLC system coupled to a Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometer was used to identify and quantify oxylipin production. For each oxylipin and PUFA their differential response was calculated with respect to a deuterated internal standard factor (ISF). To calculate oxylipin and PUFAs in the culture samples, the individual ISF was used for each oxylipin and PUFA with respect to the deuterated internal standard. PBMCs and neutrophils showed a different pattern of oxylipin production and fatty acid secretion. Lipopolysaccharide (LPS) did not stimulate oxylipin production or fatty acids secretion in PBMCs, whereas phorbol myristate acetate (PMA) stimulation increased the production rate of 5-HETE, 15-HETE, 15-HEPE, 17-DoHE, PGE2, AA, and DHA. LPS stimulation decreased 16-hydroxyl-palmitatte (16-OHPAL) production and DHA secretion in neutrophils, while PMA stimulation increased the production rate of AA and its derivate oxylipins, 5-HETE, 15-HETE, and PGE2. In conclusion, we have developed a new method to determine oxylipins derived from both saturated and unsaturated fatty acids in culture cell media. This method has enough sensitivity, and accuracy, to determine oxylipin production and fatty acid secretion by PBMCs and neutrophils.
Collapse
Affiliation(s)
- X Capó
- Institut d'Investigació Sanitària de les Illes Balears (IDISBA), E-07120 Palma, Spain; Research Group in Community Nutrition and Oxidative Stress, University of Balearic Islands, E- 07122, Palma, Spain
| | - M D Ferrer
- Institut d'Investigació Sanitària de les Illes Balears (IDISBA), E-07120 Palma, Spain; Research Group in Community Nutrition and Oxidative Stress, University of Balearic Islands, E- 07122, Palma, Spain
| | - R A Olek
- Poznan University of Physical Education, Poland
| | - E Salaberry
- Research Group in Community Nutrition and Oxidative Stress, University of Balearic Islands, E- 07122, Palma, Spain
| | - R M Gomila
- Serveis cientificotècnics, University of Balearic Islands, E- 07122, Palma, Spain
| | - G Martorell
- Serveis cientificotècnics, University of Balearic Islands, E- 07122, Palma, Spain
| | - A Sureda
- Institut d'Investigació Sanitària de les Illes Balears (IDISBA), E-07120 Palma, Spain; Research Group in Community Nutrition and Oxidative Stress, University of Balearic Islands, E- 07122, Palma, Spain; CIBEROBN - Physiopathology of Obesity and Nutrition, CB12/03/30038, University of Balearic Islands, E-07122 Palma, Spain
| | - J A Tur
- Institut d'Investigació Sanitària de les Illes Balears (IDISBA), E-07120 Palma, Spain; Research Group in Community Nutrition and Oxidative Stress, University of Balearic Islands, E- 07122, Palma, Spain; CIBEROBN - Physiopathology of Obesity and Nutrition, CB12/03/30038, University of Balearic Islands, E-07122 Palma, Spain
| | - A Pons
- Institut d'Investigació Sanitària de les Illes Balears (IDISBA), E-07120 Palma, Spain; Research Group in Community Nutrition and Oxidative Stress, University of Balearic Islands, E- 07122, Palma, Spain; CIBEROBN - Physiopathology of Obesity and Nutrition, CB12/03/30038, University of Balearic Islands, E-07122 Palma, Spain.
| |
Collapse
|
28
|
Arechavala-Lopez P, Caballero-Froilán JC, Jiménez-García M, Capó X, Tejada S, Saraiva JL, Sureda A, Moranta D. Enriched environments enhance cognition, exploratory behaviour and brain physiological functions of Sparus aurata. Sci Rep 2020; 10:11252. [PMID: 32647185 PMCID: PMC7347547 DOI: 10.1038/s41598-020-68306-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 06/23/2020] [Indexed: 12/14/2022] Open
Abstract
Environmental enrichment is considered as a recommended tool to guarantee or improve the welfare of captive fish. This study demonstrates for the first time that structural environmental enrichment enhances cognition, exploratory behaviour and brain physiological functions of gilthead seabream (Sparus aurata). Seabream was reared in groups (n = 15) during 60 days under two different treatments: enriched tanks with plant-fibre ropes (EE) or bare/non-enriched tanks (NE). Fish were then exposed to a purpose-built maze for 1 h every second day in four trials. Analysis of video recordings showed that seabream under EE conditions presented higher overall exploratory behaviour, spatial orientation and learning capability compared to seabream from NE conditions. Results from brain monoamines analyses may suggest increased recent dopaminergic activity in telencephalon, known to be involved in learning processes; and increased serotonergic activity in cerebellum, involved in the coordination of balance, movements and orientation. In addition, EE-reared fish showed increased antioxidant activity in whole brain, with no apparent oxidative damage. Structural EE seemed to induce an hormetic response on juvenile seabream, improving their welfare status during captivity. Application of this kind of physical structure might be feasible at fish farms as a passive and non-invasive tool to improve welfare of intensively cultured seabream.
Collapse
Affiliation(s)
- P Arechavala-Lopez
- Fish Ethology and Welfare Group, CCMAR, Faro, Portugal.
- Fish Ecology Group, IMEDEA (CSIC/UIB), Esporles, Spain.
| | - J C Caballero-Froilán
- Laboratory of Neurophisiology, Universitat de les Illes Balears (UIB), Palma de Mallorca, Spain
| | - M Jiménez-García
- Laboratory of Neurophisiology, Universitat de les Illes Balears (UIB), Palma de Mallorca, Spain
| | - X Capó
- Research Group in Community Nutrition and Oxidative Stress, University of Balearic Islands and Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain
- CIBEROBN (Physiopathology of Obesity and Nutrition), Palma de Mallorca, Spain
| | - S Tejada
- Laboratory of Neurophisiology, Universitat de les Illes Balears (UIB), Palma de Mallorca, Spain
- CIBEROBN (Physiopathology of Obesity and Nutrition), Palma de Mallorca, Spain
| | - J L Saraiva
- Fish Ethology and Welfare Group, CCMAR, Faro, Portugal
| | - A Sureda
- Research Group in Community Nutrition and Oxidative Stress, University of Balearic Islands and Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain
- CIBEROBN (Physiopathology of Obesity and Nutrition), Palma de Mallorca, Spain
| | - D Moranta
- Laboratory of Neurophisiology, Universitat de les Illes Balears (UIB), Palma de Mallorca, Spain
| |
Collapse
|
29
|
Laporte-Amargos J, Gudiol C, Arnan M, Puerta-Alcalde P, Carmona-Torre F, Huguet M, Albasanz-Puig A, Parody R, Garcia-Vidal C, Del Pozo JL, Batlle M, Tebé C, Rigo-Bonnin R, Muñoz C, Padullés A, Tubau F, Videla S, Sureda A, Carratalà J. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE). Trials 2020; 21:412. [PMID: 32423462 PMCID: PMC7236103 DOI: 10.1186/s13063-020-04323-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Accepted: 04/10/2020] [Indexed: 12/26/2022] Open
Abstract
Background Febrile neutropaenia (FN) is a very common complication in patients with haematological malignancies and is associated with considerable morbidity and mortality. Broad-spectrum antipseudomonal β-lactam antibiotics (BLA) are routinely used for the treatment of cancer patients with FN. However, the clinical efficacy of BLA may be diminished in these patients because they present with pathophysiological variations that compromise the pharmacokinetic (PK) parameters of these antibiotics. Optimised administration of BLA in prolonged infusions has demonstrated better clinical outcomes in critically ill patients. However, there is a paucity of data on the usefulness of this strategy in patients with FN. The aim of this study is to test the hypothesis that the administration of BLA would be clinically more effective by extended infusion (EI) than by intermittent infusion (II) in haematological patients with FN. Methods A randomised, multicentre, open-label, superiority clinical trial will be performed. Patients with haematological malignancies undergoing chemotherapy or haematopoietic stem-cell transplant and who have FN and receive empirical antibiotic therapy with cefepime, piperacillin-tazobactam or meropenem will be randomised (1:1) to receive the antibiotic by EI (during half the time of the dosing interval) in the study group, or by II (30 min) in the control group. The primary endpoint will be clinical efficacy, defined as defervescence without modifying the antibiotic treatment administered within the first 5 days of therapy. The primary endpoint will be analysed in the intention-to-treat population. The secondary endpoints will be pharmacokinetic/pharmacodynamic (PK/PD) target achievement, bacteraemia clearance, decrease in C-reactive protein, overall (30-day) case-fatality rate, adverse events and development of a population PK model of the BLA studied. Discussion Data on the usefulness of BLA administration in patients with FN are scant. Only three clinical studies addressing this issue have been published thus far, with contradictory results. Moreover, these studies had some methodological flaws that limit the interpretation of their findings. If this randomised, multicentre, phase IV, open-label, superiority clinical trial validates the hypothesis that the administration of BLA is clinically more effective by EI than by II in haematological patients with FN, then the daily routine management of these high-risk patients could be changed to improve their outcomes. Trial registration European Clinical Trials Database: EudraCT 2018–001476-37. ClinicalTrials.gov, ID: NCT04233996.
Collapse
Affiliation(s)
- J Laporte-Amargos
- Infectious Diseases Department Hospital Universitari Bellvitge, Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Gudiol
- Infectious Diseases Department Hospital Universitari Bellvitge, Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. .,University of Barcelona, Barcelona, Spain. .,Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Sevilla, Spain. .,Institut Català d'Oncologia, IDIBELL, Barcelona, Spain.
| | - M Arnan
- Clinical Haematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
| | - P Puerta-Alcalde
- Infectious Diseases Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
| | - F Carmona-Torre
- Infectious Diseases Department, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain
| | - M Huguet
- Clinical Haematology Department, Institut Català d'Oncologia-Badalona, Institut Josep Carreras (IJC), Hospital Germans Trias i Pujol, Barcelona, Spain
| | - A Albasanz-Puig
- Infectious Diseases Department Hospital Universitari Bellvitge, Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.,Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Sevilla, Spain
| | - R Parody
- Clinical Haematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
| | - C Garcia-Vidal
- Infectious Diseases Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
| | - J L Del Pozo
- Infectious Diseases Department, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain
| | - M Batlle
- Clinical Haematology Department, Institut Català d'Oncologia-Badalona, Institut Josep Carreras (IJC), Hospital Germans Trias i Pujol, Barcelona, Spain
| | - C Tebé
- Biostatistics Unit, IDIBELL, Barcelona, Spain
| | - R Rigo-Bonnin
- Clinical Laboratory Department, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain
| | - C Muñoz
- Pharmacy Department, Clinical Trial Unit, Institut Català d'Oncologia, IDIBELL, Barcelona, Spain
| | - A Padullés
- Pharmacy Department, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain
| | - F Tubau
- Microbiology Department, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain
| | - S Videla
- Clinical Pharmacology Department, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain
| | - A Sureda
- Clinical Haematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
| | - J Carratalà
- Infectious Diseases Department Hospital Universitari Bellvitge, Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.,University of Barcelona, Barcelona, Spain.,Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Sevilla, Spain
| |
Collapse
|
30
|
Mussetti A, Sureda A. Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin’s lymphoma with posttransplant cyclophosphamide. Bone Marrow Transplant 2019; 55:483-484. [DOI: 10.1038/s41409-019-0754-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 11/01/2019] [Accepted: 11/06/2019] [Indexed: 11/09/2022]
|
31
|
Domingo-Domènech E, Boumendil A, Climent F, Socié G, Kroschinsky F, Finel H, Vandenbergue E, Nemet D, Stelljes M, Bittenbring JT, Robinson S, Montoto S, Sureda A, Dreger P. Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2019; 55:633-640. [PMID: 31695173 DOI: 10.1038/s41409-019-0732-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2019] [Revised: 08/07/2019] [Accepted: 08/13/2019] [Indexed: 11/09/2022]
Abstract
Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with relapsed/refractory sALCL with special emphasis on the role of brentuximab vedotin (BV) as a bridge to allo-HCT. Forty-four patients (24 females, median age 38 years) with sALCL were included. Twenty-three patients (52%) received BV before allo-HCT; BV-treated patients were more heavily pretreated (≥3 lines of therapy in 74% vs. 38%, p = 0.04). Twenty-three patients (52%) were in complete remission (CR) at allo-HCT. Three-year nonrelapse mortality and incidence of relapse (IR) after allo-HCT were 7% and 40%, respectively. With a median follow-up of 39 (12-69) months for survivors, 3-year progression-free survival (PFS) and overall survival were 53% and 74%, respectively. Univariate analysis showed that heavily pretreated patients and those not in CR had a higher IR and a lower PFS. The use of BV before transplant did not impact on any of the outcomes. Allo-HCT is a curative therapeutic strategy in a significant proportion of patients with relapsed/refractory sALCL; BV does not seem to modify transplant-related outcomes but might be able to render more patients candidates for this curative treatment.
Collapse
Affiliation(s)
- E Domingo-Domènech
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | | | - F Climent
- Pathology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
| | - G Socié
- Hematology Department, Hopital St. Louis, Paris, France
| | | | - H Finel
- Lymphoma Working Party, EBMT, Paris, France
| | | | - D Nemet
- University Hospital Center Rebro, Zagreb, Croatia
| | - M Stelljes
- University of Münster, Muenster, Germany
| | - J T Bittenbring
- Department of Internal Medicine, University of Saarland, Homburg, Germany
| | - S Robinson
- Department of Hematology and Oncology, University Hospital Bristol, Bristol, UK
| | - S Montoto
- St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - A Sureda
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.
| | - P Dreger
- Medizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany
| | | |
Collapse
|
32
|
Bueno JL, Alegre A, López-Villar O, Querol S, Arroyo JL, Goterris R, Sureda A, García-Gala JM, Amunarriz C, Albo C, Fernández-Fuertes F, Medina L, Antelo ML, Blanquer M, Vallejo C, Canales M, Vidales-Mancha I, Duarte RF. Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document. Bone Marrow Transplant 2019; 55:811-817. [DOI: 10.1038/s41409-019-0716-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 09/27/2019] [Accepted: 09/30/2019] [Indexed: 01/15/2023]
|
33
|
Di Lorenzo A, Sobolev AP, Nabavi SF, Sureda A, Moghaddam AH, Khanjani S, Di Giovanni C, Xiao J, Shirooie S, Tsetegho Sokeng AJ, Baldi A, Mannina L, Nabavi SM, Daglia M. Corrigendum to "Antidepressive effects of a chemically characterized maqui berry extract (Aristotelia chilensis (molina) stuntz) in a mouse model of Post-stroke depression" [Food Chem. Toxicol. 129 (2019) 434-443]. Food Chem Toxicol 2019; 131:110641. [PMID: 31307821 DOI: 10.1016/j.fct.2019.110641] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- A Di Lorenzo
- Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, Pavia University, Viale Taramelli 12, Pavia, 27100, Italy.
| | - A P Sobolev
- Istituto di Metodologie Chimiche, Laboratorio di Risonanza Magnetica "Annalaura Segre", CNR, 00015, Monterotondo, Rome, Italy.
| | - S F Nabavi
- Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, P.O. Box, 19395-5487, Tehran, 19395-5487, Iran.
| | - A Sureda
- Grup de Nutrició Comunitària I Estrès Oxidatiu and CIBEROBN (Physiopathology of Obesity and Nutrition), Universitat de les Illes Balears, Palma de Mallorca, E-07122, Spain.
| | - A H Moghaddam
- Department of Biology, Faculty of Sciences, University of Mazandaran, Babolsar, Iran.
| | - S Khanjani
- Department of Physiology, Faculty of Biological Sciences, Shahid Behshti University, P.O. Box, 19615-1178, Tehran, 19615-1178, Iran.
| | - C Di Giovanni
- Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano, 49, 80131, Naples, Italy.
| | - J Xiao
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Control in Chinese Medicine, University of Macau, Macau SAR, China.
| | - S Shirooie
- School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, 6734667149, Iran.
| | - A J Tsetegho Sokeng
- Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, Pavia University, Viale Taramelli 12, Pavia, 27100, Italy.
| | - A Baldi
- Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, Pavia University, Viale Taramelli 12, Pavia, 27100, Italy.
| | - L Mannina
- Istituto di Metodologie Chimiche, Laboratorio di Risonanza Magnetica "Annalaura Segre", CNR, 00015, Monterotondo, Rome, Italy; Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, P.le Aldo Moro 5, 00185, Rome, Italy.
| | - S M Nabavi
- Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, P.O. Box, 19395-5487, Tehran, 19395-5487, Iran.
| | - M Daglia
- Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano, 49, 80131, Naples, Italy.
| |
Collapse
|
34
|
Radford J, Connors J, Younes A, Gallamini A, Ansell S, Kim W, Cheong J, Flinn I, Kalakonda N, Kaminski M, Pettengell R, Onsum M, Josephson N, Kuroda S, Liu R, Miao H, Gautam A, Trepicchio W, Sureda A. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON-1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. Hematol Oncol 2019. [DOI: 10.1002/hon.99_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Radford
- Department of Medical Oncology; University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester United Kingdom
| | - J.M. Connors
- Centre for Lymphoid Cancer; British Columbia Cancer Centre for Lymphoid Cancer; Vancouver Canada
| | - A. Younes
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Gallamini
- Research; Innovation and Statistics Department, A Lacassagne Cancer Centre; Nice France
| | - S.M. Ansell
- Department of Medicine; Mayo Clinic; Rochester United States
| | - W.S. Kim
- Hematology-Oncology; Samsung Medical Center; Seoul Republic of Korea
| | - J. Cheong
- Division of Hematology; Department of Internal Medicine, Yonsei University College of Medicine; Seoul Republic of Korea
| | - I. Flinn
- Department of Oncology; Sarah Cannon Research Institute; Nashville United States
| | - N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - M. Kaminski
- Internal Medicine; University of Michigan; Ann Arbor United States
| | - R. Pettengell
- Haematology; St George's Hospital; London United Kingdom
| | - M. Onsum
- Biomarkers; Seattle Genetics, Inc.; Bothell United States
| | - N. Josephson
- Clinical Development; Seattle Genetics, Inc.; Bothell United States
| | - S. Kuroda
- Biostatistics; Takeda Development Center Japan, Takeda Pharmaceutical Company Limited; Osaka Japan
| | - R. Liu
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - H. Miao
- OTAU Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Gautam
- Global Medical Affairs; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - W.L. Trepicchio
- Translational and Biomarker Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Sureda
- Clinical Hematology; Institut Català d'Oncologia - Hospital Duran i Reynals; Barcelona Spain
| |
Collapse
|
35
|
Dickinson M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner F, Sureda A, Salles G, Martinez J, Crump M, Thomas D, Morcos P, Ferlini C, Broeske A, Bacac M, Dimier N, Umaña P, Moore T, Weisser M, Hutchings M. CD20-TCB (RG6026), A NOVEL “2:1” FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.59_2629] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- M.J. Dickinson
- Peter MacCallum Cancer Centre; Royal Melbourne Hospital, The University of Melbourne; East Melbourne Australia
| | - F. Morschhauser
- Department of Hematology; Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées; Lille France
| | - G. Iacoboni
- Department of Hematology; Vall d'Hebron Hospital; Barcelona Spain
| | - C. Carlo-Stella
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Humanitas University; Milan Italy
| | | | - A. Sureda
- Hematology Department; Institut Català d'Oncologia Hospitalet; Barcelona Spain
| | - G. Salles
- Service d'Hématologie Clinique, Université Claude Bernard de Lyon; Lyon University Hospital; Pierre-Bénite France
| | - J. Martinez
- Servicio de Hematología; Hospital 12 de Octubre; Madrid Spain
| | - M. Crump
- Medical Oncology & Haematology; Princess Margaret Hospital; Toronto Canada
| | - D.N. Thomas
- Roche Innovation Center New York; Roche Pharma Research and Early Development (pRED); New York City United States
| | - P.N. Morcos
- Roche Innovation Center New York; Roche Pharma Research and Early Development (pRED); New York City United States
| | - C. Ferlini
- Roche Innovation Center Basel; Roche Pharma Research and Early Development (pRED); Basel Switzerland
| | - A. Broeske
- Roche Innovation Center Munich; Roche Pharma Research and Early Development (pRED); Penzberg Germany
| | - M. Bacac
- Roche Innovation Center Zurich; Roche Pharma Research and Early Development (pRED); Schlieren Switzerland
| | - N.J. Dimier
- Roche Pharma; Roche Ltd; Welwyn United Kingdom
| | - P. Umaña
- Roche Innovation Center Zurich; Roche Pharma Research and Early Development (pRED); Schlieren Switzerland
| | - T. Moore
- Roche Innovation Center Basel; Roche Pharma Research and Early Development (pRED); Basel Switzerland
| | - M. Weisser
- Roche Innovation Center Munich; Roche Pharma Research and Early Development (pRED); Penzberg Germany
| | - M. Hutchings
- Department of Haematology and Phase 1 Unit; Rigshospitalet, Copenhagen University Hospital; Copenhagen Denmark
| |
Collapse
|
36
|
Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin J, Tischer J, Gülbas Z, Labussière Wallet H, Lopez Corral L, Mohty M, Koc Y, Yakoub-Agha I, Schmid C, el Cheikh J, Arat M, Forcade E, Dreger P, Rocha V, Gutiérrez García G, Chalandon Y, Ferra C, Orvain C, Robinson S, Montoto S, Sureda A. HOW TO SELECT DONOR, STEM CELL SOURCE, AND CONDITIONING REGIMEN FOR HAPLOIDENTICAL TRANSPLANTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR LYMPHOMA: A REPORT OF THE EBMT LWP. Hematol Oncol 2019. [DOI: 10.1002/hon.108_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A. Bazarbachi
- Internal medicine American University of Beirut Medical Center Beirut, Lebanon
| | - A. Boumendil
- Lymphoma Working Party EBMT LWP Paris Office/Hôpital Saint-Antoine Paris; France
| | - H. Finel
- Lymphoma Working Party EBMT LWP Paris Office/Hôpital Saint-Antoine Paris; France
| | - L. Castagna
- Hematology Istituto Clinico Humanitas Rozzano Milano, Italy
| | - A. Dominietto
- Hematology Second Division of Hematology and Bone Marrow Transplantation, IRCCS AOU San Martino-IST Genoa, Italy
| | - D. Blaise
- Hematology Institut Paoli Calmettes Marseille, France
| | | | - J. Tischer
- Hematology Klinikum Grosshadern Munich, Germany
| | - Z. Gülbas
- Hematology Anadolu Medical Center Hospital Kocaeli, Turkey
| | | | | | - M. Mohty
- Hematology Hôpital Saint Antoine Paris, France
| | - Y. Koc
- Hematology Medical Park Hospitals Antalya, Turkey
| | | | - C. Schmid
- Hematology Klinikum Augsburg Augsburg, Germany
| | - J. el Cheikh
- Internal medicine American University of Beirut Medical Center Beirut, Lebanon
| | - M. Arat
- Hematology Florence Nightingale Sisli HospitalIstanbul, Turkey
| | | | - P. Dreger
- Hematology University of Heidelberg Heidelberg, Germany
| | - V. Rocha
- Hematology Hospital Sirio-Libanes Sao Paulo, Brazil
| | - G. Gutiérrez García
- Hematology Hospital Clinic, Universitat de Barcelona IDIBAPS, Barcelona, Spain
| | - Y. Chalandon
- Hematology Hôpitaux Universitaires Geneva, Switzerland
| | - C. Ferra
- Hematology ICO-Hospital Universitari Germans Trias i Pujol Barcelona, Spain
| | | | - S. Robinson
- Hematology Bristol Oncology Centre Bristol, United Kingdom
| | - S. Montoto
- Hematology Barts Health NHS TrustLondon, United kingdom
| | - A. Sureda
- Hematology ICO - Hospital Duran i Reynals Barcelona, Spain
| |
Collapse
|
37
|
Robinson S, Boumendil A, Finel H, Khvedelidze I, Kanfer E, Peggs K, Fuesrt S, Ram R, Marjit E, Vandenberghe E, Afanasyev B, Wulf G, Maertens J, Tsolukani A, Schapp N, Beelen D, Chalandon Y, Gurman G, Finke J, Bron D, Tischer J, Corradini P, Caballero D, Potter V, Kroger N, Burney C, Schmitz N, Sureda A, Dreger P, Montoto S. DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT-LWP STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.125_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S. Robinson
- Haematology; University Hospital Bristol; Bristol United Kingdom
| | | | | | | | - E. Kanfer
- Haematology; Hammersmith Hospital; London United Kingdom
| | - K. Peggs
- Haematology; University College London Hospital; London United Kingdom
| | - S. Fuesrt
- Haematology; Paoli Calmettes; Marseille France
| | - R. Ram
- Haematology; Sourasky; Tel Aviv Israel
| | - E. Marjit
- Haematology; Leiden University; Leiden Netherlands
| | | | - B. Afanasyev
- Haematology; Pavlov Medical University; St Petersberg Russian Federation
| | - G. Wulf
- Haematology; University Hospital; Goettingen Germany
| | - J. Maertens
- Haematology; University Hospital; Leuven Netherlands
| | - A. Tsolukani
- Haematology; City Hospital; Nottingham United Kingdom
| | - N. Schapp
- Haematology; St Radboud Hospital; Nijmegen Netherlands
| | - D. Beelen
- Haematology; University Hospital; Essen Germany
| | - Y. Chalandon
- Haematology; University Hospital; Geneva Switzerland
| | - G. Gurman
- Haematology; Ankara University; Ankara Turkey
| | - J. Finke
- Haematology; University of Freiburg; Freiburg Germany
| | - D. Bron
- Haematology; Institute Jules Bordet; Brussels Belgium
| | - J. Tischer
- Haematology; Med Klinik Klinikum Grosshaderm; Munich Germany
| | - P. Corradini
- Haematology; Istituto Nazionale dei Tumori; Milan Italy
| | | | - V. Potter
- Haematology; Kings College hospital; London United Kingdom
| | - N. Kroger
- Haematology; University Hospital Eppendorf; Hamburg Germany
| | - C. Burney
- Haematology; University Hospital Bristol; Bristol United Kingdom
| | - N. Schmitz
- Haematology; University Hospital; Muenster Germany
| | - A. Sureda
- Haematology; Oncology Institute; Barcelona Spain
| | - P. Dreger
- Haematology; University of Heidelberg; Heidleberg Germany
| | - S. Montoto
- Haematology; St Bartholomew's Hospital; London United Kingdom
| |
Collapse
|
38
|
Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol 2019; 30:612-620. [PMID: 30657848 DOI: 10.1093/annonc/mdz009] [Citation(s) in RCA: 76] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND In this work, we assessed the efficacy and safety of brentuximab vedotin (BV) plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin lymphoma (RRHL) to improve the results before autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS This was a multicenter, open-label, phase I-II trial of patients with RRHL after first-line chemotherapy. Treatment had three 21-day cycles of etoposide, solumedrol, high-dose AraC, and cisplatin. BV was administered at three dose levels (0.9, 1.2, and 1.8 mg/kg) intravenous on day ‒1 to 3 + 3 cohorts of patients. Final BV dose was 1.8 mg/kg. Responding patients proceeded to ASCT, followed by three BV courses (1.8 mg/kg, every 21 days). Main end points for evaluation were maximum tolerable dose and overall and complete response (CR) before ASCT. RESULTS A total of 66 patients were recruited (median age 36 years; range 18-66): 40 were primary refractory, 16 early relapse and 10 late relapse. There were 39 severe adverse events were reported in 22 patients, most frequently fever (n = 25, 35% neutropenic), including 3 deaths. Grade 3-4 hematological toxicity presented in 28 cases: neutropenia (n = 21), thrombocytopenia (n = 14), and anemia (n = 7). Grade ≥3-4 extrahematological adverse events (≥5%) were non-neutropenic fever (n = 13) and hypomagnesaemia (n = 3). Sixty-four patients underwent stem-cell mobilization; all collected >2×10e6/kg CD34+ cells (median 5.75; range 2.12-33.4). Overall response before transplant was 91% (CI 84% to 98%), including 70% (CRs 95% CI 59% to 81%). 60 patients were transplanted with no failure engraftments. Post-transplant response was CR in 49 patients (82% CI 73% to 91%) and partial responses in six (10% CI 5% to 15%). After a mean follow-up of 27 months, the 30-month time to treatment to failure was 74% (95% CI 68% to 80%), progression-free survival 71% (95% CI 65% to 77%), and overall survival 91% (CI 84% to 98%). CONCLUSION BRESHAP looks a safe and effective pre-transplant induction regimen, does not jeopardize transplant and allows long-term remissions and survival.
Collapse
Affiliation(s)
- R Garcia-Sanz
- Servicio de Hematología, Hospital Universitario de Salamanca; Instituto de Investigación Biomédica de Salamanca (IBSAL); Centro de Investigación del Cáncer de Salamanca, Salamanca; Servicio de Hematología, Hospital Duran i Reynals, Instituto Catalá d'Oncologia, L'Hospitalet de Llobregat, Barcelona.
| | - A Sureda
- Servicio de Hematología, Hospital Virgen del Rocio de Sevilla, Seville
| | - F de la Cruz
- Servicio de Hematología, Hospital La Paz de Madrid, Madrid
| | - M Canales
- Servicio de Hematología, Hospital Central de Asturias, Oviedo, Asturias
| | - A P Gonzalez
- Servicio de Hematología, Hospital Clínico de Valencia, Valencia
| | - J L Pinana
- Servicio de Hematología, Hospital 12 de Octubre de Madrid, Madrid
| | - A Rodriguez
- Servicio de Hematología, Hospital Son Espases de Palma de Mallorca, Palma de Mallorca
| | - A Gutierrez
- Servicio de Hematología, Hospital del Mar de Barcelona, Barcelona
| | | | | | - G Rodriguez
- Servicio de Hematología, Hospital Ramón y Cajal, Madrid
| | - J Lopez
- Servicio de Hematología, Hospital Germans Trias y Pujol de Badalona, Barcelona
| | - M Moreno
- Servicio de Hematología, Hospital Universitario de Canarias, Tenerife
| | | | | | - M D Caballero
- Servicio de Hematología, Hospital Universitario de Salamanca; Instituto de Investigación Biomédica de Salamanca (IBSAL); Centro de Investigación del Cáncer de Salamanca, Salamanca; Servicio de Hematología, Hospital Duran i Reynals, Instituto Catalá d'Oncologia, L'Hospitalet de Llobregat, Barcelona
| | - C Martinez
- Hospital Clinic de Barcelona, Barcelona, Spain
| |
Collapse
|
39
|
Arechavala-Lopez P, Capó X, Oliver-Codorniú M, Sillero-Rios J, Busquets-Cortés C, Sanchez-Jerez P, Sureda A. Fatty acids and elemental composition as biomarkers of Octopus vulgaris populations: Does origin matter? Mar Pollut Bull 2019; 139:299-310. [PMID: 30686431 DOI: 10.1016/j.marpolbul.2018.12.048] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Revised: 12/26/2018] [Accepted: 12/27/2018] [Indexed: 06/09/2023]
Abstract
The present study describes the novel use of fatty acids (FAs) and element profiles of Octopus vulgaris inhabiting three coastal areas in the W-Mediterranean Sea. These populations are exposed to different anthropogenic activities, and were compared at different geographical scales. The FA composition in the mantle of O. vulgaris exhibited significant differences in 22:6 n-3 (DHA) and 22:5 n-3 (EPA) among the sampled populations. The essential microelements Fe, Cu, Zn and Ni, and the non-essential microelements As, Sr, Al and Cd were the main contributors of variability among sampled octopus populations, with some notable differences among tissues. The variations in the FAs and elemental composition in octopus tissues were detected with other populations throughout the species distribution range, which might reflect differences in natural habitats and foraging strategies. Therefore, these may be considered biomarkers as a proxy to distinguish the origin of octopus specimens at different scales.
Collapse
Affiliation(s)
- P Arechavala-Lopez
- Fish Ecology Group, Department of Ecology of Marine Resources, Mediterranean Institute of Advance Studies (IMEDEA-CSIC/UIB), Esporles, Balearic Islands, Spain.
| | - X Capó
- Research Group on Community Nutrition and Oxidative Stress, IUNICS, University of Balearic Islands, Palma de Mallorca, Balearic Islands, Spain
| | - M Oliver-Codorniú
- Fish Ecology Group, Department of Ecology of Marine Resources, Mediterranean Institute of Advance Studies (IMEDEA-CSIC/UIB), Esporles, Balearic Islands, Spain; Research Group on Community Nutrition and Oxidative Stress, IUNICS, University of Balearic Islands, Palma de Mallorca, Balearic Islands, Spain
| | - J Sillero-Rios
- Fish Ecology Group, Department of Ecology of Marine Resources, Mediterranean Institute of Advance Studies (IMEDEA-CSIC/UIB), Esporles, Balearic Islands, Spain; Research Group on Community Nutrition and Oxidative Stress, IUNICS, University of Balearic Islands, Palma de Mallorca, Balearic Islands, Spain
| | - C Busquets-Cortés
- Research Group on Community Nutrition and Oxidative Stress, IUNICS, University of Balearic Islands, Palma de Mallorca, Balearic Islands, Spain
| | - P Sanchez-Jerez
- Department of Marine Sciences and Applied Biology, University of Alicante, Alicante, Spain
| | - A Sureda
- Research Group on Community Nutrition and Oxidative Stress, IUNICS, University of Balearic Islands, Palma de Mallorca, Balearic Islands, Spain; CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122 Palma de Mallorca, Balearic Islands, Spain
| |
Collapse
|
40
|
Sureda A, Fumadó L, Ferrer M, Garín O, Bonet X, Castells M, Mir MC, Abascal JM, Vigués F, Cecchini L, Suárez JF. Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. Health Qual Life Outcomes 2019; 17:11. [PMID: 30642340 PMCID: PMC6332524 DOI: 10.1186/s12955-019-1082-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 01/07/2019] [Indexed: 01/22/2023] Open
Abstract
Background The purpose of this study is to describe Health-Related Quality of Life (HRQoL) of localized prostate cancer patients in an Active Surveillance (AS) program, and to compare them with those undergoing radical prostatectomy (RP), external-beam radiotherapy (XRT) and brachytherapy (BT). Methods Multi-institutional pooled cross-sectional analysis on patients in an AS protocol: < 75 years old; pathologically confirmed LPC (maximum of three positive cylinders); Gleason score < 3 + 4; clinical stage T1a-T2b; and PSA < 15 ng/ml. Exclusion criteria for this study were: less than 6 months in AS, termination of AS protocol, or incomplete data. Patients in AS were matched with those treated with RP, XRT or BT from the ‘Spanish Multicentric Study of Clinically Localized Prostate Cancer’ cohort according to risk group, time from treatment selection to HRQoL survey, and age. Prostate-specific (EPIC) and generic (SF-36) HRQoL instruments were completed. Analysis was stratified by HRQoL survey moment (>or < 2.5 years from treatment selection), and age (>or < 70 years old). Results Median of time from treatment selection to HRQoL survey in the total 396 patients (99 per treatment group) was 2.4 years (range 0.5–8.3). Patients in AS presented higher (better) urinary incontinence scores than RP ones in both stratus of time from treatment selection to HRQoL survey (92.6 vs 67.0 and 81.4 vs 64.4, p < 0.01). Patients in AS for < 2.5 years presented greater sexual scores than any active treatment (p < 0.01), but only statistically higher than RP for those in AS for longer than 2.5 years. The magnitude of the differences between AS and RP groups in both EPIC domains ranged from moderate (0.7 SD) to large (1.0 SD). Regardless of treatment applied, patients presented similar and slightly increased SF-36 scores than US general population reference norms. Nonetheless, patients in AS for < 2.5 years reported worse outcomes than other treatment groups on physical health domains, especially in bodily pain (0.5–0.6 SD), and vitality (0.6–0.8 SD). Conclusions Considering patients’ well-being, AS can be a good therapeutic option due to the low impact caused on urinary continence and sexual function. However, longitudinal studies are required to take into account HRQoL evolution over time. Electronic supplementary material The online version of this article (10.1186/s12955-019-1082-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- A Sureda
- Urology Department, Hospital del Mar-IMIM, Autonomous University of Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain.,Autonomous University of Barcelona, Barcelona, Spain
| | - L Fumadó
- Urology Department, Hospital del Mar-IMIM, Autonomous University of Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain.
| | - M Ferrer
- Autonomous University of Barcelona, Barcelona, Spain.,IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain.,CIBER en Epidemiología y Salud Pública, CIBERESP, Barcelona, Spain
| | - O Garín
- IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain.,CIBER en Epidemiología y Salud Pública, CIBERESP, Barcelona, Spain.,Universitat Pompeu Fabra, Barcelona, Spain
| | - X Bonet
- Hospital Universitari de Bellvitge, l'Hospitalet de Llobregat, Barcelona, Spain
| | - M Castells
- Hospital Universitari de Bellvitge, l'Hospitalet de Llobregat, Barcelona, Spain
| | - M C Mir
- Urology Department, Hospital del Mar-IMIM, Autonomous University of Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain
| | - J M Abascal
- Urology Department, Hospital del Mar-IMIM, Autonomous University of Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain
| | - F Vigués
- Hospital Universitari de Bellvitge, l'Hospitalet de Llobregat, Barcelona, Spain
| | - L Cecchini
- Urology Department, Hospital del Mar-IMIM, Autonomous University of Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain
| | - J F Suárez
- Hospital Universitari de Bellvitge, l'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
41
|
Martínez-González MA, Buil-Cosiales P, Corella D, Bulló M, Fitó M, Vioque J, Romaguera D, Martínez JA, Wärnberg J, López-Miranda J, Estruch R, Bueno-Cavanillas A, Arós F, Tur JA, Tinahones F, Serra-Majem L, Martín V, Lapetra J, Vázquez C, Pintó X, Vidal J, Daimiel L, Delgado-Rodríguez M, Matía P, Ros E, Fernández-Aranda F, Botella C, Portillo MP, Lamuela-Raventós RM, Marcos A, Sáez G, Gómez-Gracia E, Ruiz-Canela M, Toledo E, Alvarez-Alvarez I, Díez-Espino J, Sorlí JV, Basora J, Castañer O, Schröder H, Navarrete-Muñoz EM, Zulet MA, García-Rios A, Salas-Salvadó J, Corella D, Estruch R, Fitó M, Martínez-González MA, Ros E, Salas-Salvadó J, Babio N, Ros E, Sánchez-Tainta A, Martínez-González MA, Fitó M, Schröder H, Marcos A, Corella D, Wärnberg J, Martínez-González MA, Estruch R, Fernández-Aranda F, Botella C, Salas-Salvadó J, Razquin C, Bes-Rastrollo M, Sanchez Tainta A, Vázquez Z, SanJulian Aranguren B, Goñi E, Goñi L, Barrientos I, Canales M, Sayón-Orea MC, Rico A, Basterra Gortari J, Garcia Arellano A, Lecea-Juarez O, Carlos Cenoz-Osinaga J, Bartolome-Resano J, Sola-Larraza† A, Lozano-Oloriz E, Cano-Valles B, Eguaras S, Güeto V, Pascual Roquet-Jalmar E, Galilea-Zabalza I, Lancova H, Ramallal R, Garcia-Perez ML, Estremera-Urabayen V, Ariz-Arnedo MJ, Hijos-Larraz C, Fernandez Alfaro C, Iñigo-Martinez B, Villanueva Moreno R, Martin-Almendros S, Barandiaran-Bengoetxea L, Fuertes-Goñi C, Lezaun-Indurain A, Guruchaga-Arcelus MJ, Olmedo-Cruz O, Iñigo-Martínez B, Escriche-Erviti L, Ansorena-Ros R, Sanmatin-Zabaleta R, Apalategi-Lasa J, Villanueva-Telleria J, Hernández-Espinosa MM, Arroyo-Bergera I, Herrera-Valdez L, Dorronsoro-Dorronsoro L, González JI, Sorlí JV, Portolés O, Fernández-Carrión R, Ortega-Azorín C, Barragán R, Asensio EM, Coltell O, Sáiz C, Osma R, Férriz E, González-Monje I, Giménez-Fernández F, Quiles L, Carrasco P, San Onofre N, Carratalá-Calvo A, Valero-Barceló C, Antón F, Mir C, Sánchez-Navarro S, Navas J, González-Gallego I, Bort-Llorca L, Pérez-Ollero L, Giner-Valero M, Monfort-Sáez R, Nadal-Sayol J, Pascual-Fuster V, Martínez-Pérez M, Riera C, Belda MV, Medina A, Miralles E, Ramírez-Esplugues MJ, Rojo-Furió M, Mattingley G, Delgado MA, Pages MA, Riofrío Y, Abuomar L, Blasco-Lafarga N, Tosca R, Lizán L, Guillem-Saiz P, Valcarce AM, Medina MD, Monfort R, de Valcárcel S, Tormo N, Felipe-Román O, Lafuente S, Navío EI, Aldana G, Crespo JV, Llosa JL, González-García L, Raga-Marí R, Pedret Llaberia R, Gonzalez R, Sagarra Álamo R, París Palleja F, Balsells J, Roca JM, Basora Gallisa T, Vizcaino J, Llobet Alpizarte P, Anguera Perpiñá C, Llauradó Vernet M, Caballero C, Garcia Barco M, Morán Martínez MD, García Rosselló J, Del Pozo A, Poblet Calaf C, Arcelin Zabal P, Floresví X, Ciutat Benet M, Palau Galindo A, Cabré Vila JJ, Dolz Andrés F, Boj Casajuana J, Ricard M, Saiz F, Isach A, Sanchez Marin Martinez M, Bulló M, Babio N, Becerra-Tomás N, Mestres G, Basora J, Mena-Sánchez G, Barrubés Piñol L, Gil Segura M, Papandreou C, Rosique Esteban N, Chig S, Abellán Cano I, Ruiz García V, Salas-Huetos A, Hernandez P, Canudas S, Camacho-Barcia L, García-Gavilán J, Diaz A, Castañer O, Muñoz MA, Zomeño MD, Hernaéz A, Torres L, Quifer M, Llimona R, Gal LA, Pérez A, Farràs M, Elosua R, Marrugat J, Vila J, Subirana I, Pérez S, Muñoz MA, Goday A, Chillaron Jordan JJ, Flores Lerroux JA, Benaiges Boix D, Farré M, Menoyo E, Muñoz-Aguayo D, Gaixas S, Blanchart G, Sanllorente A, Soria M, Valussi J, Cuenca A, Forcano L, Pastor A, Boronat A, Tello S, Cabañero M, Franco L, Schröder H, De la Torre R, Medrano C, Bayó J, García MT, Robledo V, Babi P, Canals E, Soldevila N, Carrés L, Roca C, Comas MS, Gasulla G, Herraiz X, Martínez A, Vinyoles E, Verdú JM, Masague Aguade M, Baltasar Massip E, Lopez Grau M, Mengual M, Moldon V, Vila Vergaz M, Cabanes Gómez Ciurana R, Gili Riu M, Palomeras Vidal A, Garcia de la Hera M, González Palacios S, Torres Collado L, Valera Gran D, Compañ Gabucio L, Oncina Canovas A, Notario Barandiaran L, Orozco Beltran D, Pertusa Martínez S, Cloquell Rodrigo B, Hernándis Marsán MV, Asensio A, Altozano Rodado MC, Ballester Baixauli JJ, Fernándis Brufal N, Martínez Vergara MC, Román Maciá J, Candela García I, Pedro Cases Pérez E, Tercero Maciá C, Mira Castejón LA, de los Ángeles García García I, Zazo JM, Gisbert Sellés C, Sánchez Botella C, Fiol M, Moñino M, Colom A, Konieczna J, Morey M, Zamanillo R, Galmés AM, Pereira V, Martín MA, Yáñez A, Llobera J, Ripoll J, Prieto R, Grases F, Costa A, Fernández-Palomeque C, Fortuny E, Noris M, Munuera S, Tomás F, Fiol F, Jover A, Janer JM, Vallespir C, Mattei I, Feuerbach N, del Mar Sureda M, Vega S, Quintana L, Fiol A, Amador M, González S, Coll J, Moyá A, Abete I, Cantero I, Cristobo C, Ibero-Baraibar I, Lezáun Burgui MD, Goñi Ruiz N, Bartolomé Resano R, Cano Cáceres E, Elcarte López T, Echarte Osacain E, Pérez Sanz B, Blanco Platero I, Andueza Azcárate SA, Gimeno Aznar A, Ursúa Sesma E, Ojeda Bilbao B, Martinez Jarauta J, Ugalde Sarasa L, Rípodas Echarte B, Güeto Rubio MV, Fernández-Crehuet Navajas J, Gutiérrez Bedmar M, García Rodriguez A, Mariscal Larrubia A, Carnero Varo M, Muñoz Bravo C, Barón-López FJ, Fernández García JC, Pérez-Farinós N, Moreno-Morales N, del C Rodríguez-Martínez M, Pérez-López J, Benavente-Marín JC, Crespo Oliva E, Contreras Fernández E, Carmona González FJ, Carabaño Moral R, Torres Moreno S, Martín Ruíz MV, Alcalá Cornide M, Fuentes Gómez V, Criado García J, Jiménez Morales AI, Delgado Casado N, Ortiz Morales A, Torres Peña JD, Gómez Delgado FJ, Rodríguez Cantalejo F, Caballero Villaraso J, Alcalá JF, Peña Orihuela PJ, Quintana Navarro G, Casas R, Domenech M, Viñas C, Castro-Barquero S, Ruiz-León AM, Sadurní M, Frontana G, Villanueva P, Gual M, Soriano R, Camafort M, Sierra C, Sacanella E, Sala-Vila A, Cots JM, Sarroca I, García M, Bermúdez N, Pérez A, Duaso I, de la Arada A, Hernández R, Simón C, de la Poza MA, Gil I, Vila M, Iglesias C, Assens N, Amatller M, Rams LL, Benet T, Fernández G, Teruel J, Azorin A, Cubells M, López D, Llovet JM, Gómez ML, Climente P, de Paula L, Soto J, Carbonell C, Llor C, Abat X, Cama A, Fortuny M, Domingo C, Liberal AI, Martínez T, Yañez E, Nieto MJ, Pérez A, Lloret E, Carrazoni C, Belles AM, Olmos C, Ramentol M, Capell MJ, Casas R, Giner I, Muñoz A, Martín R, Moron E, Bonillo A, Sánchez G, Calbó C, Pous J, Massip M, García Y, Massagué MC, Ibañez R, Llaona J, Vidal T, Vizcay N, Segura E, Galindo C, Moreno M, Caubet M, Altirriba J, Fluxà G, Toribio P, Torrent E, Anton JJ, Viaplana A, Vieytes G, Duch N, Pereira A, Moreno MA, Pérez A, Sant E, Gené J, Calvillo H, Pont F, Puig M, Casasayas M, Garrich A, Senar E, Martínez A, Boix I, Sequeira E, Aragunde V, Riera S, Salgado M, Fuentes M, Martín E, Ubieto A, Pallarés F, Sala C, Abilla A, Moreno S, Mayor E, Colom T, Gaspar A, Gómez A, Palacios L, Garrigosa R, García Molina L, Riquelme Gallego B, Cano Ibañez N, Maldonado Calvo A, López Maldonado A, Garrido EM, Baena Dominguez A, García Jiménez F, Thomas Carazo E, Jesús Turnes González A, González Jiménez F, Padilla Ruiz F, Machado Santiago J, Martínez Bellón MD, Pueyos Sánchez A, Arribas Mir L, Rodríguez Tapioles R, Dorador Atienza F, Baena Camus L, Osorio Martos C, Rueda Lozano D, López Alcázar M, Ramos Díaz F, Cruz Rosales Sierra M, Alguacil Cubero P, López Rodriguez A, Guerrero García F, Tormo Molina J, Ruiz Rodríguez F, Rekondo J, Salaverria I, Alonso-Gómez A, Belló MC, Loma-Osorio A, Tojal L, Bruyel P, Goicolea L, Sorto C, Casi Casanellas A, Arnal Otero ML, Ortueta Martínez De Arbulo J, Vinagre Morgado J, Romeo Ollora J, Urraca J, Sarriegui Carrera MI, Toribio FJ, Magán E, Rodríguez A, Castro Madrid S, Gómez Merino MT, Rodríguez Jiménez M, Gutiérrez Jodra M, López Alonso B, Iturralde Iriso J, Pascual Romero C, Izquierdo De La Guerra A, Abbate M, Aguilar I, Angullo E, Arenas A, Argelich E, Bibiloni MM, Bisbal Y, Bouzas C, Busquets C, Capó X, Carreres S, De la Peña A, Gallardo L, Gámez JM, García B, García C, Julibert A, Llompart I, Mascaró CM, Mateos D, Montemayor S, Pons A, Ripoll T, Rodríguez T, Salaberry E, Sureda A, Tejada S, Ugarriza L, Valiño L, Bernal López MR, Macías González M, Ruiz Nava J, Fernández García JC, Muñoz Garach A, Vilches Pérez A, González Banderas A, Alcaide Torres J, Vargas Candela A, León Fernández M, Hernández Robles R, Santamaría Fernández S, Marín JM, Valdés Hernández S, Villalobos JC, Ortiz A, Álvarez-Pérez J, Díaz Benítez EM, Díaz-Collado F, Sánchez-Villegas A, Pérez-Cabrera J, Casañas-Quintana LT, García-Guerra RB, Bautista-Castaño I, Ruano-Rodríguez C, Sarmiento de la Fe F, García-Pastor JA, Macías-Gutiérrez B, Falcón-Sanabria I, Simón-García C, Santana-Santana AJ, Álvarez-Álvarez JB, Díaz-González BV, Castillo Anzalas JM, Sosa-Also RE, Medina-Ponce J, Abajo Olea S, Adlbi Sibai A, Aguado Arconada A, Álvarez L, Carriedo Ule E, Escobar Fernández M, Ferradal García JI, Fernández Vázquez JP, García González M, González Donquiles C, González Quintana C, González Rivero F, Lavinia Popescu M, López Gil JI, López de la Iglesia J, Marcos Delgado A, Merino Acevedo C, Reguero Celada S, Rodríguez Bul M, Vilorio-Marqués L, Santos-Lozano JM, Miró-Moriano L, Domínguez-Espinaco C, Vaquero-Díaz S, García-Corte FJ, Santos-Calonge A, Toro-Cortés C, Pelegrina-López N, Urbano-Fernández V, Ortega-Calvo M, Lozano-Rodríguez J, Rivera-Benítez I, Caballero-Valderrama M, Iglesias-Bonilla P, Román-Torres P, Corchado-Albalat Y, Mayoral-Sánchez E, de Cos AI, Gutierrez S, Artola S, Galdon A, Gonzalo I, Más S, Sierra R, Luca B, Prieto L, Galera A, Gimenez-Gracia M, Figueras R, Poch M, Freixedas R, Trias F, Sarasa I, Fanlo M, Lafuente H, Liceran M, Rodriguez-Sanchez A, Pallarols C, Monedero J, Corbella X, Corbella E, Altés A, Vinagre I, Mestres C, Viaplana J, Serra M, Vera J, Freitas T, Ortega E, Pla I, Ordovás JM, Micó V, Berninches L, Concejo MJ, Muñoz J, Adrián M, de la Fuente Y, Albertos C, Villahoz E, Cornejo ML, Gaforio JJ, Moraleda S, Liétor N, Peis JI, Ureña T, Rueda M, Ballesta MI, Moreno Lopera C, Aragoneses Isabel C, Sirur Flores MA, Ceballos de Diego M, Bescos Cáceres T, Peña Cereceda Y, Martínez Abad M, Cabrera Vela R, González Cerrajero M, Rubio Herrera MA, Torrego Ellacuría M, Barabash Bustelo A, Ortiz Ramos M, Garin Barrutia U, Baños R, García-Palacios A, Cerdá Micó C, Estañ Capell N, Iradi A, Fandos Sánchez M. Cohort Profile: Design and methods of the PREDIMED-Plus randomized trial. Int J Epidemiol 2018; 48:387-388o. [PMID: 30476123 DOI: 10.1093/ije/dyy225] [Citation(s) in RCA: 159] [Impact Index Per Article: 26.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/08/2018] [Indexed: 01/04/2023] Open
Affiliation(s)
- Miguel A Martínez-González
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Pilar Buil-Cosiales
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
- Atención Primaria, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain
| | - Dolores Corella
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine, University of Valencia, Valencia, Spain
| | - Monica Bulló
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Rovira i Virgili University, Department of Biochemistry and Biotechnology, Human Nutrition Unit, IISPV, Hospital Universitari Sant Joan de Reus, Reus, Spain
| | - Montserrat Fitó
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Mèdica (IMIM), Barcelona, Spain
| | - Jesús Vioque
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Miguel Hernandez University, ISABIAL-FISABIO, Alicante, Spain
| | - Dora Romaguera
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Clinical Epidemiology and Public Health Department, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain
| | - J Alfredo Martínez
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- University of Navarra, Department of Nutrition, Food Science and Physiology, IDISNA, Pamplona, Spain
| | - Julia Wärnberg
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Nursing, School of Health Sciences, University of Málaga-IBIMA, Málaga, Spain
| | - Jose López-Miranda
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain
| | - Ramón Estruch
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Internal Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Aurora Bueno-Cavanillas
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine, University of Granada, Granada, Spain
| | - Fernando Arós
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Cardiology, University Hospital Araba, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain
| | - Josep A Tur
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, Palma de Mallorca, Spain
| | - Francisco Tinahones
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Virgen de la Victoria Hospital, Department of Endocrinology, University of Málaga, Málaga, Spain
| | - Lluis Serra-Majem
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- University of Las Palmas de Gran Canaria, Research Institute of Biomedical and Health Sciences (IUIBS), Preventive Medicine Service, Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, Las Palmas, Spain
| | - Vicente Martín
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Institute of Biomedicine (IBIOMED), University of León, León, Spain
| | - Jose Lapetra
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain
| | - Clotilde Vázquez
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Endocrinology, Fundación Jiménez-Díaz, Madrid, Spain
| | - Xavier Pintó
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - Josep Vidal
- CIBER Diabetes y enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Endocrinology, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Lidia Daimiel
- Nutritional Genomics and Epigenomics Group, IMDEA Food, CEI UAM + CSIC, Madrid, Spain
| | - Miguel Delgado-Rodríguez
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Division of Preventive Medicine, Faculty of Medicine, University of Jaén, Jaén, Spain
| | - Pilar Matía
- Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain
| | - Emilio Ros
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Lipid Clinic, Department of Endocrinology and Nutrition, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain
| | - Fernando Fernández-Aranda
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Eating Disorders Unit, Department of Psychiatry, University Hospital of Bellvitge-IDIBELL, Hospitalet del Llobregat, Barcelona, Spain
| | - Cristina Botella
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Basic and Clinical Psychology and Psychobiology, Universitat Jaume I, Castellón de la Plana, Spain
| | - María Puy Portillo
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Nutrition and Food Science, Faculty of Pharmacy and Lucio Lascaray Research Center, Universidad del País Vasco (UPV/EHU), Vitoria, Spain
| | - Rosa M Lamuela-Raventós
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Nutrition, Food Science and Gastronomy, XaRTA, INSA, -UB, School of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain
| | - Ascensión Marcos
- Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), Madrid, Spain
| | - Guillermo Sáez
- Department of Biochemistry and Molecular Biology, Faculty of Medicine and Odontology, University Hospital Dr. Peset, University of Valencia, Valencia, Spain
| | | | - Miguel Ruiz-Canela
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
| | - Estefania Toledo
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
| | - Ismael Alvarez-Alvarez
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
| | - Javier Díez-Espino
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain
- Atención Primaria, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain
| | - José V Sorlí
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Preventive Medicine, University of Valencia, Valencia, Spain
| | - Josep Basora
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Rovira i Virgili University, Department of Biochemistry and Biotechnology, Human Nutrition Unit, IISPV, Hospital Universitari Sant Joan de Reus, Reus, Spain
| | - Olga Castañer
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Mèdica (IMIM), Barcelona, Spain
| | - Helmut Schröder
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Mèdica (IMIM), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Eva María Navarrete-Muñoz
- CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Miguel Hernandez University, ISABIAL-FISABIO, Alicante, Spain
| | - Maria Angeles Zulet
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- University of Navarra, Department of Nutrition, Food Science and Physiology, IDISNA, Pamplona, Spain
| | - Antonio García-Rios
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain
| | - Jordi Salas-Salvadó
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Rovira i Virgili University, Department of Biochemistry and Biotechnology, Human Nutrition Unit, IISPV, Hospital Universitari Sant Joan de Reus, Reus, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Sillero-Ríos J, Sureda A, Capó X, Oliver-Codorniú M, Arechavala-Lopez P. Biomarkers of physiological responses of Octopus vulgaris to different coastal environments in the western Mediterranean Sea. Mar Pollut Bull 2018; 128:240-247. [PMID: 29571370 DOI: 10.1016/j.marpolbul.2018.01.032] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Revised: 01/11/2018] [Accepted: 01/16/2018] [Indexed: 06/08/2023]
Abstract
The increase of pollutants in coastal seawater could produce several harmful biological effects on marine organisms related to the production of reactive oxygen species (ROS) causing cellular and tissue damages through oxidative stress mechanisms. Common octopuses (Octopus vulgaris) inhabiting coastal areas under high anthropogenic activity of Mallorca (W-Mediterranean Sea) have the ability to control oxidative damage by triggering antioxidant enzyme responses. Analyzing the digestive glands, octopuses from human-altered coastal areas showed higher activity of superoxide dismutase (SOD), catalase (CAT) and glutathione S-transferase (GST) compared to octopuses from non-influenced coastal waters (i.e. marine reserve area). Higher metallothionein (MT) concentrations and lack of malondialdehyde (MDA) variations also reflect adaptations of O. vulgaris to polluted areas. This is the first study assessing the levels of the oxidative stress biomarkers on O. vulgaris in the Mediterranean Sea, revealing their usefulness to assess diverse environmental pollution effects on this relevant ecological and commercial species.
Collapse
Affiliation(s)
- J Sillero-Ríos
- Research Group on Community Nutrition and Oxidative Stress, IUNICS, University of Balearic Islands, Palma de Mallorca, Balearic Islands, Spain; Fish Ecology Group, Department of Ecology of Marine Resources, Mediterranean Institute of Advance Studies (IMEDEA-CSIC/UIB), 07190, Esporles, Balearic Islands, Spain
| | - A Sureda
- Research Group on Community Nutrition and Oxidative Stress, IUNICS, University of Balearic Islands, Palma de Mallorca, Balearic Islands, Spain; CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma de Mallorca, Balearic Islands, Spain.
| | - X Capó
- Research Group on Community Nutrition and Oxidative Stress, IUNICS, University of Balearic Islands, Palma de Mallorca, Balearic Islands, Spain
| | - M Oliver-Codorniú
- Research Group on Community Nutrition and Oxidative Stress, IUNICS, University of Balearic Islands, Palma de Mallorca, Balearic Islands, Spain; Fish Ecology Group, Department of Ecology of Marine Resources, Mediterranean Institute of Advance Studies (IMEDEA-CSIC/UIB), 07190, Esporles, Balearic Islands, Spain
| | - P Arechavala-Lopez
- Fish Ecology Group, Department of Ecology of Marine Resources, Mediterranean Institute of Advance Studies (IMEDEA-CSIC/UIB), 07190, Esporles, Balearic Islands, Spain
| |
Collapse
|
43
|
Capó X, Martorell M, Busquets-Cortés C, Sureda A, Riera J, Drobnic F, Tur JA, Pons A. Effects of dietary almond- and olive oil-based docosahexaenoic acid- and vitamin E-enriched beverage supplementation on athletic performance and oxidative stress markers. Food Funct 2018; 7:4920-4934. [PMID: 27841405 DOI: 10.1039/c6fo00758a] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Functional beverages based on almonds and olive oil and enriched with α-tocopherol and docosahexaenoic acid (DHA) could be useful in modulating oxidative stress and enhancing physical performance in sportsmen. The aim of this work was to evaluate the effects of supplementation with functional beverages on physical performance, plasma and erythrocyte fatty acids' and polyphenol handling, oxidative and nitrative damage, and antioxidant and mitochondrial gene expression in young and senior athletes. Athletes performed maximal exercise tests before and after one month of dietary supplementation and blood samples were taken immediately before and one hour after each test. The beverages did not alter performance parameters during maximal exercise. Supplementation increased polyunsaturated and reduced saturated plasma fatty acids while increasing the DHA erythrocyte content; it maintained basal plasma and blood polyphenol levels, but increased the blood cell polyphenol concentration in senior athletes. Supplementation protects against oxidative damage although it enhances nitrative damage in young athletes. The beverages enhance the gene expression of antioxidant enzymes in peripheral blood mononuclear cells after exercise in young athletes.
Collapse
Affiliation(s)
- X Capó
- Research Group on Community Nutrition and Oxidative Stress, Science Laboratory of Physical Activity, Department of Fundamental Biology and Health Sciences, University of Balearic Islands, 07122 Palma de Mallorca, Spain and CIBER: CB12/03/30038 Fisiopatología de la Obesidad la Nutrición, CIBEROBN, Instituto de Salud Carlos III (ISCIII), University of Balearic Islands, 07122 Palma de Mallorca, Spain.
| | - M Martorell
- Research Group on Community Nutrition and Oxidative Stress, Science Laboratory of Physical Activity, Department of Fundamental Biology and Health Sciences, University of Balearic Islands, 07122 Palma de Mallorca, Spain and Departamento de Nutrición y Dietética, Facultad de Farmacia, Universidad de Concepción, 4070386 Concepción, Chile
| | - C Busquets-Cortés
- Research Group on Community Nutrition and Oxidative Stress, Science Laboratory of Physical Activity, Department of Fundamental Biology and Health Sciences, University of Balearic Islands, 07122 Palma de Mallorca, Spain and CIBER: CB12/03/30038 Fisiopatología de la Obesidad la Nutrición, CIBEROBN, Instituto de Salud Carlos III (ISCIII), University of Balearic Islands, 07122 Palma de Mallorca, Spain.
| | - A Sureda
- Research Group on Community Nutrition and Oxidative Stress, Science Laboratory of Physical Activity, Department of Fundamental Biology and Health Sciences, University of Balearic Islands, 07122 Palma de Mallorca, Spain and CIBER: CB12/03/30038 Fisiopatología de la Obesidad la Nutrición, CIBEROBN, Instituto de Salud Carlos III (ISCIII), University of Balearic Islands, 07122 Palma de Mallorca, Spain.
| | - J Riera
- Sports Physiology Dept. CAR, Sant Cugat del Valles, GIRSANE, Barcelona 08174, Spain
| | - F Drobnic
- Sports Physiology Dept. CAR, Sant Cugat del Valles, GIRSANE, Barcelona 08174, Spain
| | - J A Tur
- Research Group on Community Nutrition and Oxidative Stress, Science Laboratory of Physical Activity, Department of Fundamental Biology and Health Sciences, University of Balearic Islands, 07122 Palma de Mallorca, Spain and CIBER: CB12/03/30038 Fisiopatología de la Obesidad la Nutrición, CIBEROBN, Instituto de Salud Carlos III (ISCIII), University of Balearic Islands, 07122 Palma de Mallorca, Spain.
| | - A Pons
- Research Group on Community Nutrition and Oxidative Stress, Science Laboratory of Physical Activity, Department of Fundamental Biology and Health Sciences, University of Balearic Islands, 07122 Palma de Mallorca, Spain and CIBER: CB12/03/30038 Fisiopatología de la Obesidad la Nutrición, CIBEROBN, Instituto de Salud Carlos III (ISCIII), University of Balearic Islands, 07122 Palma de Mallorca, Spain.
| |
Collapse
|
44
|
Alomar C, Sureda A, Capó X, Guijarro B, Tejada S, Deudero S. Microplastic ingestion by Mullus surmuletus Linnaeus, 1758 fish and its potential for causing oxidative stress. Environ Res 2017; 159:135-142. [PMID: 28800471 DOI: 10.1016/j.envres.2017.07.043] [Citation(s) in RCA: 200] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 06/14/2017] [Accepted: 07/24/2017] [Indexed: 05/12/2023]
Abstract
A total of 417 striped red mullet, Mullus surmuletus, were analyzed to study microplastic ingestion and livers of fish were assessed to study effects of microplastics. Nearly one third (27.30%) of the individuals were quantified to ingest microplastics although there was no evidence of oxidative stress or cellular damage in the liver of fish which had ingested microplastics. A small increase in the activity of glutathione S-transferase (GST) of M. surmuletus was detected which could be suggesting an induction of the detoxification systems but these findings should be tested in laboratory conditions under a controlled diet and known concentration of microplastics. Fish from trammel fisheries, operating closer to land and targeting larger individuals, showed higher mean ingestion values than fish from trawling fisheries, and were related to body size, as microplastics ingested increased with total fish length. Consequently, ingestion values of microplastics were not related to sampling distance from land giving further evidence of the ubiquity of microplastics in the marine environment. Finally, Fourier Transform Infrared Spectroscopy (FTIR) analysis showed that the vast majority of microplastics were filament type and polyethylene terephthalate (PET) was the main identified component.
Collapse
Affiliation(s)
- C Alomar
- Instituto Español de Oceanografía, Centro Oceanográfico de Baleares, Muelle de Poniente s/n, 07015 Palma de Mallorca, Spain.
| | - A Sureda
- Research Group in Community Nutrition and Oxidative Stress, Department of Basic Biology and Health Sciences, University of Balearic Islands, Ctra. Valldemossa, km 7,5, Ed. Guillem Colom, 07122 Balearic Islands, Spain; CIBEROBN (Fisiopatología de la Obesidad y la Nutrición CB12/03/30038), Instituto de Salud Carlos III, Balearic Islands, Spain
| | - X Capó
- Research Group in Community Nutrition and Oxidative Stress, Department of Basic Biology and Health Sciences, University of Balearic Islands, Ctra. Valldemossa, km 7,5, Ed. Guillem Colom, 07122 Balearic Islands, Spain
| | - B Guijarro
- Instituto Español de Oceanografía, Centro Oceanográfico de Baleares, Muelle de Poniente s/n, 07015 Palma de Mallorca, Spain
| | - S Tejada
- Experimental Laboratory, Research Unit, Son Llàtzer Hospital, IUNICS, Ctra. Manacor, km 4, 07198 Palma de Mallorca, Balearic Islands, Spain
| | - S Deudero
- Instituto Español de Oceanografía, Centro Oceanográfico de Baleares, Muelle de Poniente s/n, 07015 Palma de Mallorca, Spain
| |
Collapse
|
45
|
Salas Q, Climent F, Tapia G, Riasol M, Mercadal S, Domingo Domenech E, Oliveira A, Moreno-Velázquez M, Garcia O, Aguilera C, Fernandez de Sevilla A, Sureda A, Sancho J, González Barca E. CD30 expression in diffuse large B-cell lymphoma correlates with non-GCB subtype but does not have prognostic impact in patients treated with first line R-CHOP/R-CHOP-like. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Q. Salas
- Department of Hematology; Institut Català d'Oncologia Hospitalet; Barcelona Spain
| | - F. Climent
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - G. Tapia
- Pathology Department; Hospital Germans Trías i Pujol; Badalona, Barcelona Spain
| | - M. Riasol
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - S. Mercadal
- Department of Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - E. Domingo Domenech
- Department of Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - A. Oliveira
- Department of Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - M. Moreno-Velázquez
- Hematology Department; ICO-IJC Hospital Germans Trías i Pujol; Badalona, Barcelona Spain
| | - O. Garcia
- Hematology Department; ICO-IJC Hospital Germans Trías i Pujol; Badalona, Barcelona Spain
| | - C. Aguilera
- Department of Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - A. Fernandez de Sevilla
- Hematology Department and Department of Clinical Sciences; Institut Català d'Oncologia Hospitalet, IDIBELL, and University of Barcelona; L'Hospitalet de Llobregat, Barcelona Spain
| | - A. Sureda
- Department of Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - J. Sancho
- Hematology Department; ICO-IJC Hospital Germans Trías i Pujol; Badalona, Barcelona Spain
| | - E. González Barca
- Hematology Department and Department of Clinical Sciences; Institut Català d'Oncologia Hospitalet, IDIBELL, and University of Barcelona; L'Hospitalet de Llobregat, Barcelona Spain
| |
Collapse
|
46
|
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs K, Afanasyev B, Diez-Martin J, Corradini P, Socié G, Robinson S, Gutiérrez-García G, Bonifazi F, Yakoub-Agha I, Gülbas Z, Bloor A, Delage J, Esquirol A, Malladi R, Scheid C, Ghesquières H, Montoto S, Dreger P, Sureda A. BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_71] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Bazarbachi
- Department of internal medicine; American University of Beirut; Beirut Lebanon
| | - A. Boumendil
- EBMT LWP Paris Office; Hôpital Saint-Antoine; Paris France
| | - H. Finel
- EBMT LWP Paris Office; Hôpital Saint-Antoine; Paris France
| | - M. Mohty
- Service d'Hématologie et Thérapie Cellulaire; Hôpital Saint Antoine; Paris France
| | - L. Castagna
- Department of Hematology; Istituto Clinico Humanitas; Milan Italy
| | - D. Blaise
- Department of internal medicine; Institut Paoli Calmettes; Marseille France
| | - K. Peggs
- Department of internal medicine; University College London Hospital; London UK
| | - B. Afanasyev
- Department of internal medicine; First State Pavlov Medical University of St. Petersburg; St. Petersburg Russian Federation
| | - J. Diez-Martin
- Department of internal medicine; Hospital Gregorio Marañón; Madrid Spain
| | - P. Corradini
- IRCCS Istituto Nazionale dei Tumori; University of Milano; Milan Italy
| | - G. Socié
- Department of internal medicine; Hopital St. Louis; Paris France
| | - S. Robinson
- Department of internal medicine; University Hospital Bristol; Bristol UK
| | | | - F. Bonifazi
- S.Orsola-Malpighi Hospital; Bologna University; Bologna Italy
| | | | - Z. Gülbas
- Department of internal medicine; Anadolu Medical Center Hospital; Kocaeli Turkey
| | - A. Bloor
- Department of internal medicine; Christie NHS Trust Hospital; Manchester UK
| | - J. Delage
- Department of internal medicine; CHU Lapeyronie; Montpellier France
| | - A. Esquirol
- Department of internal medicine; Hospital Santa Creu i Sant Pau; Barcelona Spain
| | - R. Malladi
- Department of internal medicine; Queen Elizabeth Hospital; Birmingham UK
| | - C. Scheid
- Department of internal medicine; University of Cologne; Cologne Germany
| | - H. Ghesquières
- Department of internal medicine; Centre Hospitalier Lyon Sud; Lyon France
| | - S. Montoto
- Department of Haemato-oncology; St Bartholomew's Hospital; London UK
| | - P. Dreger
- Dept Medicine V; University of Heidelberg; Heidelberg Germany
| | - A. Sureda
- Department of Haematology; Institut Catala d'Oncologia, Hospital Duran I Reynals; Barcelona Spain
| |
Collapse
|
47
|
Andrade Campos M, Mercadal S, Domingo Domenech E, Paredes V, Aguilera C, Oliveira A, de la Banda E, Climent F, Parody R, Fernandez de Sevilla A, Sureda A, Gonzalez Barca E. Short course of R-HyperCVAD/MTX/ARA-C followed by ASCT as first-line therapy in mantle cell lymphoma patients prolongs progression-free survival to more than 9 years. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Andrade Campos
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL, CIBERER, ISCIII; Barcelona Spain
| | - S. Mercadal
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - E. Domingo Domenech
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - V. Paredes
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - C. Aguilera
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - A. Oliveira
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - E. de la Banda
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL; Barcelona Spain
| | - F. Climent
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL; Barcelona Spain
| | - R. Parody
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - A. Fernandez de Sevilla
- Hematology, Department Clinical Sciences, Institut Català d'Oncologia Hospitalet, IDIBELL.; University of Barcelona; Barcelona Spain
| | - A. Sureda
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - E. Gonzalez Barca
- Hematology, Department Clinical Sciences, Institut Català d'Oncologia Hospitalet, IDIBELL.; University of Barcelona; Barcelona Spain
| |
Collapse
|
48
|
Salas Q, Domingo Domenech E, Mercadal S, Oliveira A, Aguilera C, De la Banda E, Climent F, Lucas A, Garcia N, Baca C, Fernandez de Sevilla A, Sureda A, González Barca E. Effective treatments are required for patients with diffuse large B-cell lymphoma (DLBCL) with primary refractory disease. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_92] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Q.Q. Salas
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - E. Domingo Domenech
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - S. Mercadal
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - A. Oliveira
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - C. Aguilera
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - E. De la Banda
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL, Hospitalet del LLobregat; Barcelona Spain
| | - F. Climent
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL, Hospitalet del LLobregat; Barcelona Spain
| | - A. Lucas
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - N. Garcia
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - C. Baca
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - A. Fernandez de Sevilla
- Department of Hematology, Institut Català d'Oncologia Hospitalet, IDIBELL, Barcelona, Spain. IDIBELL. Departament of Clinical Sciences; University of Barcelona, Hospitalet del LLobregat; Barcelona Spain
| | - A. Sureda
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - E. González Barca
- Department of Hematology, Institut Català d'Oncologia Hospitalet, IDIBELL, Barcelona, Spain. IDIBELL. Departament of Clinical Sciences; University of Barcelona, Hospitalet del LLobregat; Barcelona Spain
| |
Collapse
|
49
|
Domingo Domenech E, Boumendil A, Climent F, Socié G, Kroschinsky F, Finel H, Vandenbergue E, Nemet D, Stelljes M, Bittenbring J, Montoto S, Sureda A, Dreger P. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) FOR PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (R/R SALCL). A RETROSPECTIVE ANALYSIS OF THE LYMPHOMA WORKING PARTY-EBMT. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | - F. Climent
- Pathology; Hospital Universitari de Bellvitge, Hospitalet de Llobregat; Spain
| | - G. Socié
- Hematology; Hospital St Louis; Paris France
| | | | - H. Finel
- EBMT, Lymphoma Working Party; Paris France
| | - E. Vandenbergue
- Hematology; St. James's Hospital; Dublin Ireland, Republic of
| | - D. Nemet
- Hematology; University Hospital Rebro; Zagreb Croatia
| | - M. Stelljes
- Hematology; University of Münster; Münster Germany
| | - J. Bittenbring
- BMT Unit; University of Saarland University Hospital; Homburg Germany
| | - S. Montoto
- Hematology; St Bartholomew's hospital, Barts Health NHS Trust; London UK
| | - A. Sureda
- Hematology; Institut Catala d'Oncologia, Hospitalet de Llobregat; Spain
| | - P. Dreger
- Hematology; University of Heidelberg, Germany; Heidelberg Germany
| |
Collapse
|
50
|
Montoro Gómez J, Pomares H, Merchán B, Molero A, Alonso E, Fernández M, Gallur L, Grau J, Salamero O, Tazón-Vega B, Blanco A, Ortega M, Sureda A, Arnán M, Valacárcel D. An IPSS-R Cutoff Point of 3 Stratified Myelodysplastic Syndromes Patients Into Two Risk Groups. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30366-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|